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To Mike
To mom and dad
The opposite of every truth is just as true.
Hermann Hesse
ABSTRACT
The role of atrial fibrillation (AF) in brain and cognitive aging (e.g., cognitive 
decline and dementia) is still unclear. In this doctoral thesis, we aimed to inves-
tigate the temporal trends and potential determinants of dementia incidence, the 
occurrence of AF and the pattern of use of antithrombotic drugs, the association 
of AF with cognitive decline and dementia, and the association of AF with vari-
ous structural brain abnormalities among older adults. Data were derived from 
the population-based Kungsholmen Project (KP), the Swedish National study on 
Aging and Care in Kungsholmen (SNAC-K), and the SNAC-K MRI sub-study. 
Study I. In the KP (1987-1989 to 1997-1998) and the SNAC-K (2001-2004 to 
2010-2013) cohorts, 440 out of 1473 persons and 388 out of 1746 persons devel-
oped incident dementia, respectively. The incidence rate of dementia declined by 
30% during the second decade (hazard ratio [HR] = 0.70; 95% confidence interval 
[CI]: 0.61-0.80). The decline was evident mainly among women and in people with 
low education. Vascular disorders and cognitive reserve factors explained only a 
small proportion of the decline (HR = 0.77, 95% CI: 0.65-0.90). 
Study II. In SNAC-K, 328 (9.8%) of 3363 persons were ascertained to have AF 
at baseline. The prevalence of AF increased with advancing age and was slightly 
higher than previously reported. From 2001-2004 to 2007-2010, the use of antico-
agulant drugs substantially increased among people with AF, especially in people 
with high risk of stroke or low risk of bleeding. However, still two-thirds of those 
at high stroke risk remained untreated with anticoagulants. 
Study III. At baseline of SNAC-K, 243 (9.1%) of the 2685 dementia-free par-
ticipants were identified to have AF. During the 9-year follow-up period, 279 
(11.4%) people were ascertained to have incident AF and 399 (14.9%) developed 
incident dementia. As a time-varying variable, AF was associated with a faster 
annual decline in global cognition (β coefficient = -0.24, 95% CI: -0.31, -0.16) and 
a higher risk of all-cause dementia (HR = 1.40, 95% CI: 1.11-1.77) and vascular 
and mixed dementia (HR = 1.88, 95% CI: 1.09-3.23), but not Alzheimer’s disease. 
Among participants with AF, use of anticoagulant drugs, but not antiplatelets, 
was associated with a reduced risk of dementia (HR = 0.40, 95% CI: 0.18-0.92).
Study IV. In the SNAC-K MRI sample, 39 (7.2%) of 540 people were identi-
fied to have AF at baseline. AF was associated with a higher odds ratio (OR) of 
the presence of cerebral infarcts (OR=3.98, 95% CI: 1.31-12.09). During the 
6-year follow-up period, among 248 people who were free of cerebral infarcts, 
AF was associated with a faster increase in white matter hyperintensity vol-
ume  (β  coefficient = 0.45, 95% CI: 0.04-0.85) and lateral ventricular volume 
 (β  coefficient = 0.57, 95% CI: 0.13-1.02).
Conclusion. Dementia incidence had declined among older adults from the late 
1980s to the early 2010s, and improved cardiovascular health and cognitive reserve 
could only partially explain the decline. In addition, AF is common in old age, and 
despite an increase in the use of anticoagulant drugs among older people with AF 
over time, still two-thirds of those with high risk of stroke remained untreated. 
Furthermore, AF is associated with an accelerated cognitive decline and a greater 
risk of dementia, and the use of anticoagulant drugs may prevent older patients 
with AF from developing dementia. Finally, AF is associated with a faster increase 
in white matter lesions and brain atrophy in the absence of cerebral infarcts. 
Keywords: aging, atrial fibrillation, dementia, cognitive decline, prevalence, inci-
dence, time trend, anticoagulant drugs, antiplatelet drugs, stroke risk, bleeding risk, 
cerebral small vessel disease, magnetic resonance imaging, population-based study 
SAMMANFATTNING
Rollen av förmaksflimmer i hjärnan och kognitivt åldrande (t.ex. kognitiv nedgång 
och demens) är fortfarande oklar. I denna doktorsavhandling syftade vi till att under-
söka tidstrender och potentiella faktorer för förekomst av demens, förekomsten av 
AF och mönstret för användning av antitrombotiska läkemedel, associeringen av 
AF med kognitiv nedgång och demens, samt associeringen mellan AF och olika 
strukturella hjärnabnormaliteter hos äldre vuxna. Data från det befolkningsbaserad 
Kungsholmen-projektet (KP), the Swedish National study on Aging and Care in 
Kungsholmen (SNAC-K) och SNAC-K MRI- delstudie har använts i detta projekt. 
Studie I. I KP (1987-1989 till 1997-1998) och SNAC-K (2001-2004 till  2010-2013) 
kohorterna, diagnosticerades 440 av 1473 personer respektive 388 av 1746 personer 
med demens. Förekomsten av demens sjönk med 30% under det andra decenniet 
(riskkvot [HR] = 0.70; 95% konfidensintervall [CI]: 0.61-0.80). Minskningen var 
tydlig främst bland kvinnor och personer med låg utbildning. Kärlstörningar och kog-
nitiva reservfaktorer förklarade endast en liten del av nedgången  (HR = 0.77, 95% 
CI: 0.65-0.90).
Studie II. I SNAC-K identifierades 328 (9.8%) av 3363 personer med AF vid 
baslinjen. Förekomsten av AF ökade med stigande ålder och var något högre än 
det som tidigare rapporterats. Från 2001-2004 till 2007-2010 ökade användningen 
av antikoagulantia avsevärt bland personer med AF, särskilt hos personer med 
hög risk för stroke eller låg risk för blödning. Men två tredjedelar av de med hög 
stroke risk förblev fortfarande obehandlade med antikoagulantia.
Studie III. Vid baslinjen för SNAC-K identifierades 243 (9.1%) av de 2685 
demensfria deltagarna med AF. Under den 9-åriga uppföljningsperioden utvecklade 
279 (11.4%) personer med incident AF och 399 (14.9%) demens. Som en tids-
varierande variabel förknippades AF med en snabbare årlig minskning av global 
kognition (ß-koefficient = -0.24, 95% CI: -0.31, -0.16) och en högre risk för demens 
av alla orsaker (HR = 1.40, 95 % Cl: 1.11-1.77) och vaskulär och blandad demens 
(HR = 1.88, 95% Cl: 1.09-3.23), men inte Alzheimers sjukdom. Bland deltagarna 
med AF var användning av antikoagulantia, men inte antiplateletter, associerad 
med en minskad risk för demens (HR = 0.40, 95% CI: 0.18-0.92).
Studie IV. I SNAC-K MRI-subgruppen identifierades 39 (7.2%) av 540 personer med 
AF vid baslinjen. AF var associerat med högre odds (OR) av cerebrala infarkter (OR 
= 3.98, 95% CI: 1.31-12.09). Under den 6-åriga uppföljningsperioden förknippades 
AF bland 248 personer som var fria från hjärninfarkt med en snabbare ökning av 
hyperintensitetsvolym av vit hjärnsubstans (ß-koefficient = 0.45, 95% CI: 0.04-0.85) 
och lateral ventrikulär volym (P-koefficient = 0.57, 95% Cl: 0.13-1.02).
Slutsats. Förekomsten av demens har minskat bland äldre vuxna från slutet av 
1980-talet till början av 2010-talet, och förbättrad kardiovaskulär hälsa och kognitiv 
reserv kunde bara delvis förklara nedgången. AF är vanligt i ålderdom, och trots 
en ökning i användningen av antikoagulantia bland äldre med AF genom tiden, 
förblev två tredjedelar med hög risk för stroke fortfarande obehandlade. Dessutom 
är AF associerat med en snabbare kognitiv nedgång och en större risk för demens, 
och användningen av antikoagulantia kan förhindra att äldre patienter med AF 
utvecklar demens. Slutligen är AF förknippat med en snabbare ökning av skador 
i vit hjärnsubstans och hjärnatrofi i frånvaro av cerebrala infarkter.
Nyckelord: åldrande, förmaksflimmer, demens, kognitiv nedgång, prevalens, 
incidens, tidsutveckling, antikoagulantia, antiplateletter, strokerisk, blödningsrisk, 
cerebral småkärlsjukdom, magnetisk resonansavbildning, befolkningsbaserad studie
摘要ߗ
心房纤颤在脑结构改变和认知功能障碍中的作用仍不明确。在该博士论文中，我们研究了
老年痴呆发病率的趋势和及其潜在决定因素、心房纤颤的患病率和房颤病人中抗血栓药物
的使用情况、心房纤颤与认知功能下降和老年痴呆风险的关联、以及心房纤颤与脑结构改
变的关联。该论文涉及的所有数据来源于基于斯德哥尔摩社区老年人群的 ൂ൬൥൞൪ൟ൦ൣ൤൜൥ߗ
േ൩൦ൡ൜൚൫（ൂേ）、ൊ൅സഺതൂߗൊ൫൬൛൰、以及嵌入 ൊ൅സഺതൂ的核磁共振成像子研究ߗൊ൅സഺതൂߗൄ൉ീߗ
൪൫൬൛൰。ߗ
课题一：在 ൂേߗനഫമപ名研究对象中，നരയമതനരയര到 നരരമതനരരയ间有 ഫഫധ个新发痴呆病例；
在 ൊ൅സഺതൂߗനമഫഭ名研究对象中，ഩധധനതഩധധഫ到 ഩധനധതഩധനപ间有 പയയߗ个新发痴呆病例。老年
痴呆的发病风险在第二个十年显著下降了 പധജ（ി൉ߗഴߗധഥമധലߗരബജߗഺീറߗധഥഭനതധഥയധ），并在
女性和低教育水平人群中尤为显著。心脑血管健康的改善和认知功能储蓄的提升只解释了
一小部分老年痴呆发病风险的降低趋势（ി൉ߗഴߗധഥമമണߗരബജߗഺീറߗധഥഭബതധഥരധ）。ߗ
课题二：在 പപഭപ个参加 ൊ൅സഺതൂ基线调查的老年人中，പഩയ（രഥയജ）人被诊断患有心房纤
颤。心房纤颤的患病率随着年龄的增加而显著增长并且高于既往研究。从 ഩധധനതഩധധഫ到
ഩധധമതഩധനധ间，心房纤颤病人中抗凝血药的使用率显著升高，特别是在高中风风险和低出
血风险的人群中。然而仍然有三分之二的高中风风险者没有进行抗凝血药物治疗。ߗ
课题三：ൊ൅സഺതൂߗ基线调查中，ߗഩഭയബ名研究对象无老年痴呆，其中 ഩഫപ（രഥനജ）人患有心
房纤颤。在 ര年随访过程中，新发 ഩമര（നനഥഫജ）例心房纤颤和 പരര（നഫഥരജ）例老年痴呆。
心房纤颤与认知功能下降呈显著相关（βߗ൚൦൜൝൝ൠ൚ൠ൜൥൫ߗഴߗതധഥഩഫണߗരബജߗഺീറߗതധഥപനണߗത
ധഥനഭ）。心房纤颤也与老年痴呆风险（ി൉ߗഴߗനഥഫധണߗരബജߗഺീറߗനഥനനതനഥമമ）以及血管性和混
合痴呆风险（ി൉ߗഴߗനഥയയണߗരബജߗഺീറߗനഥധരതപഥഩപ）呈显著相关，但与阿茲海默症关联无统计
学显著性。在心房纤颤患者中，使用抗凝血药与老年痴呆风险降低有关（ി൉ߗഴߗധഥഫധണߗരബജߗ
ഺീറߗധഥനയതധഥരഩ），而抗血小板药的使用与老年痴呆风险关联无统计学显著性。ߗ
课题四：在 ബഫധ个参加 ൊ൅സഺതൂߗൄ൉ീ基线调查的人群中，പര（മഥഩജ）人患有心房纤颤。心房
纤颤患者中脑梗塞（脑影像学诊断）风险较高（െ൉ߗഴߗപഥരയണߗരബജߗഺീറߗനഥപനതനഩഥധര）。在
ഩഫയ个参加 ഭ年随访并无脑梗塞的研究对象中，心房纤颤与大脑白质病变增加（βߗ
൚൦൜൝൝ൠ൚ൠ൜൥൫ߗഴߗധഥഫബണߗരബജߗഺീറߗധഥധഫതധഥയബ）以及脑室容积增高（βߗ൚൦൜൝൝ൠ൚ൠ൜൥൫ߗഴߗധഥബമണߗ
രബജߗഺീറߗധഥനപതനഥധഩ）呈显著相关。ߗ
结论：老年痴呆发病率从 നരയധ年代末到 ഩധനധ年代初呈下降趋势，心脑血管健康的改善和
认知功能储蓄的提升不能完全解释此下降趋势。心房纤颤在老年人中比较普遍；虽然房颤
病人中抗凝血药的使用率上升了，仍然有三分之二的高中风风险病人始终未使用抗凝血
药。此外，心房纤颤与认知功能下降和老年痴呆风险有关联，而抗凝血药的使用能在房颤
病人中大幅度降低老年痴呆的风险。在无脑梗塞的情况下，心房纤颤与脑白质病变和脑萎
缩仍存在相关性。ߗ
关键词：衰老；心房纤颤；老年痴呆；认知功能下降；患病率；发病率；时间趋势；抗凝
血药；抗血小板药；中风风险；出血风险；全脑小血管病变；核磁共振成像；队列研究ߗ
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11 INTRODUCTION
1.1 Population aging and the dementia epidemic
Due to dropping fertility rates and longer life expectancy, the world’s populations 
are aging rapidly, with varying degree and pace of aging across countries.[1,2] 
According to the United Nations, just 9% of the global population was aged 60 years 
and above in 1990. This proportion has risen to 11% by 2010 and is projected to 
reach 23% by 2100. Globally, the number of people aged 60 years and older will 
double in size, reaching 1 billion in 2020 and surpassing 2 billion by 2100.[3] 
Notably, the oldest-old population (e.g., people aged 80 years and older) repre-
sents the fastest growing segment of the society, with the proportion increasing at 
a projected rate of 0.4% per decade from 2020 to 2100. In Europe, the proportion 
of oldest-old will be 5% in 2020, higher than the world average level (2%).[3,4]
As one of the most devastating disorders in old age, dementia refers to a clinical 
syndrome characterized by progressive decline in multiple cognitive domains that 
is severe enough to affect social or professional functioning. Advancing age is the 
strongest risk factor for dementia, and as a result of population aging, more and 
more older adults are at an increased risk of dementia. According to the World 
Alzheimer Report, 46.8 million persons worldwide were affected by dementia in 
2015, and this number is expected to reach 75 million by 2030 and 132 million 
by 2050. In 2018, dementia has become a trillion dollar disease, and its global 
economic cost will rise to 2 trillion US dollars by 2030.[5] Given the projected 
vast increase in the future burden of dementia, WHO in 2012 had recognized 
dementia as a global public health priority. Global coordinated efforts, such as the 
London G8 Dementia Summit in 2013 and the first WHO Ministerial Conference 
on dementia in 2015, have been initiated to make effective response to the chal-
lenges of an increasing dementia epidemic.[6]
1.2 Is the incidence of dementia changing over time? 
Despite the projected increase in the absolute number of people with dementia, 
a growing body of literature has suggested a potential decline in the incidence of 
dementia in Europe and North America.[7–9] Investigating the temporal trends in 
dementia incidence is challenging, as changes in diagnostic measures and other 
methodological aspects over time can affect the estimates and comparisons of 
dementia incidence.[10] Robust evidence needs to come from population-based 
cohorts using constant study designs and diagnostic measures over time.[9,11] 
So far, nine population-based studies worldwide, in which consistent study meth-
ods were used, have reported the temporal trends in the incidence of dementia 
in the UK,[12,13] the Netherlands,[14] France,[15] the USA,[16–19] and Japan 
2[20] (Table 1). Despite differences in study methods, all studies have indicated a 
declining trend in the incidence of all-cause dementia among older adults from the 
1980s to the 2010s, except for a US study which reported a stable annual incidence 
of Alzheimer’s disease (AD) from 1998 to 2012[19] and the Japanese study that 
showed an increasing incidence of all-cause dementia from 1988 to 2012[16]. On 
the other hand, studies using health administrative data have reported mixed results, 
where some studies supported a decreasing incidence of dementia [21–24] and 
others did not [25–28]. In Sweden, a register-based study of people aged ≥65 years 
showed an increase in the incidence of hospital diagnosis of dementia from 1987 to 
2010, followed by a decline from 2010 to 2016.[26] So far direct evidence is lack-
ing from population-based studies in Sweden on the temporal trends of dementia 
incidence, although a previous report using two population-based cohorts inferred 
a potential decline from the 1980s to the 2000s in Stockholm based on prevalence 
and survival data.[29] Furthermore, few studies have investigated whether and to 
what extent changes in dementia protective and risk factors over time could explain 
the observed decline. It has been suggested that improved formal education, better 
lifestyle, and successful primary prevention of cardiovascular diseases might be 
the driving force behind the decreasing risk of dementia.[9] Notably, owning to 
the effective preventative and therapeutic interventions for vascular risk factors, 
the incidence of stroke and major cardiovascular diseases has declined in Western 
Europe and North America over the past decades,[22,30,31] which might partly 
contribute to a decreasing incidence of dementia. 
1.3 Atrial fibrillation in old age
Characterized by irregular activation and ineffective contraction of the atrium, 
atrial fibrillation (AF) is the most common sustained cardiac arrhythmia affecting 
predominantly the older population.[32] It was estimated that AF confers a lifetime 
risk of 25% among people aged 55 years and above.[33] As the global population 
ages, AF constitutes a major public health challenge with increased risk of heart 
failure, myocardial infarction, stroke, and mortality.[34,35]  According to the 
Global Burden of Disease Study, approximately 46 million people globally were 
estimated to have AF in 2016, a 40% increase from 34 million in 2010.[36,37] In 
the European Union, 9 million adults aged 55 years and over had AF in 2010, and 
this number was expected to double by 2060 to 18 million.[38]
31.3.1 The prevalence of atrial fibrillation
Table 2 shows a summary of major studies reporting age-specific prevalence of 
AF, where the prevalence increases successively with advancing age.[33,39–48] 
However, previously reported figures vary substantially across studies and coun-
tries. For instance, the prevalence of AF ranges from 2% to 10% in people aged 
70-74 years and 3% to 12% in people aged 75-79 years; in the oldest old (age 
≥80 years), the variations are even larger, spanning from 5% to 22%. 
Comparisons of AF prevalence across studies might be hampered by differences 
in study populations and case ascertainment. Most available data concerning AF 
prevalence come from hospital samples, health registers, or people who were 
willing to take part in periodic health examinations. Studies based on these data 
are more likely to suffer from selection bias, therefore reporting relatively lower 
prevalence. In addition, AF is often undiagnosed due to silent AF and many peo-
ple with AF may never come to medical attention,[49,50] therefore studies using 
only medical records to identify AF cases could have missed a big proportions of 
asymptomatic cases from the general population and thus underestimated the true 
prevalence. Only a few studies used population-based cohorts and multiple sources 
(e.g., medical records, electrocardiogram (ECG), and physical examination) to 
identify people with AF, and these studies generally reported higher overall and 
age-specific prevalence of AF.[33,39,51] 
4Table 1. A summary of population-based studies reporting temporal trends in 
dementia incidence
Study, year, 
country 
Study population Baseline cohorts Diagnostic criteria Temporal 
trends
Rajan et al. 
2019,[19] USA
People aged ≥65 years liv-
ing in southern Chicago 
Cycle 1: 1998-00 (n=842)
Cycle 2: 2001-03 (n=643)
Cycle 3: 2004-06 (n=734)
Cycle 4: 2007-09 (n=656)
Cycle 5: 2010-12 (n=415)
NINCDS-ADRDA for 
Alzheimer’s disease
Stable
Sullivan  
et al. 2018, 
[18] USA
People aged ≥65 years liv-
ing in rural Pennsylvania 
1: 1987 (n=1681)
2: 2006 (n=1982)
Clinical Dementia 
Rating ≥1.0 
Decline
Ahmadi-
Abhari et al. 
2017,[13]  
UK
People aged ≥50 years 
from the 1998-2001 
Health Survey for England 
responders
Wave 1: 2002-03 (n=10525)
Wave 2: 2004-05 (n=9225)
Wave 3: 2006-07 (n=8155)
Wave 4: 2008-09 (n=8386)
Wave 5: 2010-11 (n=9767)
Either combination of 
cognitive impairment 
and ADL disability or 
self-report
Decline
Ohara et al. 
2017,[20] 
Japan
People aged ≥60 years liv-
ing in Hisayama
1: 1988 (n=803)
2: 2002 (n=1231)
DSM-III-R criteria Increase
Matthew et al. 
2016, [12] UK
People aged ≥65 years 
living in three areas of 
England
1: 1990-93 (n=7635)
2: 2008-11 (n=7762)
Algorithm 
(GMS-AGECAT) 
Decline
Satizabal et 
al 2016,[17] 
USA
People aged ≥60 years liv-
ing in Framingham
Period 1: 1977-83 (n=2457)
Period 2: 1986-91 (n=2135)
Period 3: 1992-98 (n=2333)
Period 4: 2004-08 (n=2090)
DSM-IV criteria Decline
Gao et al. 
2016,[16] USA
African Americans aged 
≥70 years in Indianapolis, 
USA; Yoruba aged ≥70 
years in Ibadan, Nigeria 
Indianapolis:
1: 1992 (n=1440)
2: 2001 (n=1835)
Ibadan:
1: 1992 (n=1174)
2: 2001 (n=1895)
DSM-III and ICD-10 
criteria
Decline in 
Indianapolis; 
no change in 
Ibadan
Grasset et al. 
2016, [15] 
France
People aged ≥65 years liv-
ing in Bordeaux
1: 1988-89 (n=1469)
2: 1999-2000 (n=2104)
Algorithm (based on 
MMSE and IADL) and 
DSM-III-R criteria
Algorithm: 
decline; 
DSM-III-R: no 
change
Schrijvers et 
al. 2012,[14] 
Netherlands
People aged ≥60 years liv-
ing in Rotterdam
1: 1990 (n=5727)
2: 2000 (n=1769)
DSM-III-R criteria Decline
MMSE=Mini-Mental State Examination; DSM=Diagnostic and Statistical Manual of Mental Disorders; 
IADL=Instrumental activities of daily living; ICD=International Statistical Classification of Diseases; 
GMS=Geriatric Mental State
5Ta
bl
e 
2.
 A
 s
um
m
ar
y 
of
 m
aj
or
 s
tu
di
es
 r
ep
or
ti
ng
 a
ge
-s
pe
ci
fic
 p
re
va
le
nc
e 
of
 a
tr
ia
l f
ib
ri
lla
ti
on
Au
th
or
s 
Co
un
try
,s
tu
dy
pe
rio
d
 H
ee
rin
ga
et
 a
l.
[3
3]
De
nm
ar
k,
19
90
-9
3
An
de
rs
so
n
et
al
.[
39
]
Sw
ed
en
,2
01
1
M
aj
ee
d
et
 a
l.
[4
0]
UK
,1
99
4-
98
Ca
rlo
et
 a
l.
[4
1]
Ita
ly,
20
16
M
ur
ph
ye
t a
l. 
[4
2]
Sc
ot
la
nd
,2
00
1-
02
 W
ilk
e
et
 a
l.
[4
3]
Ge
rm
an
y,
20
07
-0
8
Go
,e
t a
l.
[4
4]
US
A,
19
96
-9
7
Na
cc
ar
el
lie
t a
l.
[4
5]
US
A,
20
04
-0
5
Zh
ou
et
 a
l.
[4
6]
Ch
in
a,
20
00
Ko
da
ni
et
 a
l.
[4
7]
Ja
pa
n,
20
15
Sp
ai
n,
20
10
-1
2
Go
m
ez
-D
ob
la
se
t a
l.
[4
8]
St
ud
yp
op
ul
a
on
Po
pu
la
o
n-
ba
se
d
st
ud
y o
fp
eo
pl
e
liv
in
g
in
Ro
e
rd
am
(n
=6
80
8)
Al
lin
ha
bi
ta
nt
so
fN
or
th
er
n
Hä
lsi
ng
la
nd
(n
=6
55
32
)
Pa
e
nt
sr
eg
ist
er
ed
in
21
1
ge
ne
ra
lp
ra
c
ce
s
(n
=1
.4
m
illi
on
)
Al
lp
a
en
ts
fro
m
 th
re
e
pr
im
ar
y-
ca
re
pr
ac
c
es
(n
=4
52
8)
Pa
e
nt
sf
ro
m
55
pr
im
ar
y
ca
re
pr
ac
c
es
(n
=3
62
15
5)
Cl
ai
m
sd
at
a
of
tw
o 
m
an
da
to
ry
in
su
ra
nc
e
fu
nd
s(
n=
8.
3
m
illi
on
)
Pe
op
le
en
ro
lle
d
in
a
he
al
th
m
ai
nt
en
an
ce
or
ga
ni
za
o
n
(n
=1
.9
m
illi
on
)
Cl
ai
m
sd
at
a
fro
m
M
ar
ke
tS
ca
n
an
d
M
ed
ica
re
da
ta
ba
se
s(
n=
21
.6
m
illi
on
)
Ra
nd
om
sa
m
pl
e 
of
14
co
ho
rt
sf
ro
m
13
pr
ov
in
ce
s(
n=
29
07
9)
Pa
r
cip
an
ts
in
na
o
na
l h
ea
lth
in
su
ra
nc
e
an
d
an
nu
al
he
al
th
ch
ec
ku
ps
(n
=1
23
03
)
Ra
nd
om
sa
m
pl
e 
of
pa
e
nt
sf
ro
m
47
ho
sp
ita
ls
(n
=8
34
3)
61.3.2 Antithrombotic treatment in atrial fibrillation
The loss of effective atrial contraction can lead to formation of blood clots in the 
atrium, which tend to propagate to the brain.[52] It has been well established that 
AF substantially increases the risk of ischemic stroke.[35] However, this elevated 
risk of stroke is not homogenous and may change with the presence or absence 
of additional risk factors such as advancing age, prior stroke events, heart failure, 
and hypertension.[53,54] These factors have thus been used to build stroke risk 
stratification schemes, in which stroke risks are categorized into low, intermediate, 
and high risk strata in AF patients.[55] Generally, current international consensus 
guidelines suggest the initiation of anticoagulant treatment with either Vitamin 
K antagonists (e.g., warfarin) or novel oral anticoagulant drugs in people with 
intermediate or high risk of stroke. The use of antiplatelet therapy (e.g., aspirin) 
among older AF patients should be minimized, as the evidence for stroke preven-
tion with antiplatelets in AF is weak, with a potential for harm, as compared to 
anticoagulant drugs.[56,57]
Risk stratification schemes. The most commonly used scheme for stroke risk 
assessment is the CHADS2 score, which contains major clinical risk factors for 
stroke (scoring 1 point each for age ≥75 years, heart failure, hypertension, and 
diabetes and 2 points for ischemic stroke/transient ischemic attack (TIA)).[56] A 
CHADS2 score ≥2 indicates high stroke risk, while a score of 1 and 0 indicates 
intermediate and low stroke risk, respectively.
The main drawback of the CHADS2 score is that it does not reliably identify 
patients who are at “truly low risk” for stroke, as many patients with a CHADS2 
score of 0, hence do not need anticoagulation, still have an annual stroke rate of 
>1.5%.[54,58] The 2010 European Society of Cardiology (ESC) guidelines for 
AF management recommended the use of CHA2DS2-VASc score, in which more 
clinical relevant risk factors were added (scoring 1 point each for heart failure, 
diabetes, hypertension, vascular disorders including peripheral arterial diseases 
and myocardial infarction, age 65-74, and female sex, and 2 points each for age 
≥75 years and ischemic stroke/TIA).[56] Multiple studies have shown that the 
CHA2DS2-VASc score is better at identifying “truly low risk” AF patients and per-
forms the same as CHADS2 score in terms of predicting stroke events.[54,59,60] 
In addition to risk of stroke, decision-making for thromboprophylaxis also needs 
to balance the risk of major bleeding (e.g., intracranial hemorrhage), which is a 
complication of anticoagulant drugs and confers a high risk of mortality and dis-
ability.[61] Consensus guidelines have recommended the use of HAS-BLED score 
(1 point each for hypertension, abnormal renal function, abnormal liver function, 
ischemic stroke/TIA, major bleeding, labile international normalized ratio (INR), 
age ≥65 years, and 1 or 2 points for drug/alcohol use) to assess the risk of major 
bleeding for AF patients, and a HAS-BLED score ≥3 indicates a high bleeding 
risk.[56,57,62] 
7Underuse of anticoagulant drugs in patients with AF. Contrary to guideline-
based expectations, AF patients are often under-treated in the real-world settings, 
and suboptimal use of anticoagulant drugs has been frequently reported. Figure 1 
shows the percentage of use of anticoagulant drugs in AF patients with a CHADS2 
score ≥2 or a CHA2DS2-VASc score ≥2 in previous investigations,[39,63–81] 
most of which are based on register data or hospital samples and very few used 
population-based cohorts. A proportion of anticoagulant therapy below 70% was 
reported in most of these studies using either scoring systems (Figure 1). For 
example, in two register-based studies in Sweden, around half of AF patients with 
high risk of stroke were using anticoagulant drugs 2006-2014.[71,77] The large-
scale register-based studies of AF patients in the US showed that less than half of 
the patients were on anticoagulant treatment even among people with a CHADS2 
score >3,[76] and that untreated patients are at a greater risk of death and thrombo-
embolism/TIA.[72] Physicians’ concerns of major bleeding are one of the reasons 
behind the under-use of anticoagulant agents in older adults, yet very few studies 
have taken into account bleeding risk (e.g., HAS-BLED score) when assessing 
the patterns of anticoagulant therapy. However, a high HAS-BLED score per se 
should not be used to exclude AF patients from anticoagulant therapy but rather 
call for closer follow-up of the patients, as several studies have shown that the risk 
of thromboembolism without use of anticoagulant drugs substantially outweighs 
the risk of major bleeding with anticoagulant therapy.[82,83] 
Apart from the worrisome underuse of anticoagulant drugs in AF patients, only a 
few studies have examined the secular change in the use of anticoagulant drugs.
[75,84–87] Although a progressive improvement in the treatment of AF has been 
seen in several studies, many patients at high risk of stroke were still not receiving 
anticoagulant drugs. For instance, a US study using the Medicare data reported a 
significant annual increase from 1992 to 2002 in the use of warfarin coupled with 
a decline in the incidence of ischemic stroke among AF patients; yet still over 30% 
of AF patients were not on anticoagulant treatment by the end of follow-up.[85] 
A Japanese study reported that the prescription of warfarin among AF patients 
steadily increased from 41% in 2004 to 56% in 2010, but almost 40% of those 
with a CHADS2 score ≥2 were not using anticoagulant drugs in 2010.[75] So far 
no population-based studies have examined this temporal trend considering both 
stroke and bleeding risk stratification schemes.
1.4 Atrial fibrillation and cognitive aging
Owing to the lack of curative treatment for dementia, exploring its modifiable risk 
factors has become a promising strategy to reduce the enormous economic and 
societal burden associated with cognitive dysfunction. Nine potentially modifiable 
risk factors over the life course (i.e., low education, hearing loss, hypertension, 
8diabetes, obesity, smoking, physical inactivity, social isolation, and depression) 
have been identified for AD and dementia. However, only 35% of all dementia 
cases are attributable to the combination of these modifiable risk factors, with 
another 7% accounted by apolipoprotein E (APOE) ε4 allele, the major genetic 
risk factor for AD.[88] Over the past two decades, continuous investigations have 
identified AF as a new yet important risk factor for cognitive decline and dementia 
among older adults. 
Figure 1. Percentage of use of anticoagulant drugs among AF patients with a CHADS2 
score ≥2 (A) or a CHA2DS2-VASc score ≥2 (B).
91.4.1 Atrial fibrillation, cognitive decline, and dementia
AF and dementia share a number of risk factors such as advancing age and cardio-
vascular risk factors including diabetes, hypertension, and high cholesterol.[89,90] 
AF increases the risk of ischemic stroke by 4- to 5-fold,[35] and the association 
between AF and dementia has been repeatedly reported among patients with a 
prior stroke.[91,92] During the past few years, evidence has emerged that AF may 
increase the risk of cognitive decline and dementia irrespective of the presence of 
stroke in the general older population.  
Table 3 shows a summary of longitudinal studies examining the relationship 
between AF and cognitive decline or dementia;[93–106] these studies have sub-
stantial heterogeneity in study designs, case ascertainment of AF, and assessment 
of cognitive function. Nevertheless, most studies have reported an association of 
AF with an increased risk of cognitive decline and dementia, especially among 
younger-old people. For instance, the Rotterdam study including 6514 community-
dwelling people followed up for 20 years found AF to be significantly associated 
with incident dementia only among people aged <67 years.[97] Similarly, the 
Whitehall II Study involving more than 7400 participants aged 45-69 years dem-
onstrated that AF was associated with faster cognitive decline and higher risk of 
dementia over 26 years of follow-up.[96] More recently, the Atherosclerosis Risk 
in Communities (ARIC) study showed a faster annual cognitive decline associ-
ated with AF over 20 years among 12512 participants (mean age 57 years).[95] 
Among very old people (e.g., 75 years and above), results are rather mixed, where 
some studies report an association[100,106,107] and others do not.[102,104,105] 
Notably, incident AF has rarely been considered in previous studies; this is important 
given that the association between prevalent AF and dementia might be underes-
timated due to later diagnosis of AF and survival effect. In addition, although AF 
is presumed to affect the brain mainly through vascular pathways, a considerable 
proportion of dementia cases are attributable to both vascular and AD pathology 
in the brain [108,109] and very few studies have elucidated the association of AF 
with different dementia subtypes.  
1.4.2 Do anticoagulant drugs prevent dementia in atrial fibrillation 
patients?
Oral anticoagulant drugs have been a potent and evidence-based treatment to 
prevent AF-related thromboembolism; by meta-analyses, warfarin is associated 
with a 64% decreased risk of stroke among AF patients compared to no treat-
ment.[110,111] It is plausible that such treatment could also act against cognitive 
deterioration by reducing the number of cerebral infarcts. Whether AF-related 
dementia can be prevented by anticoagulant treatment has been under active 
investigations, yet there is still a paucity of evidence regarding the association of 
10
anticoagulant drugs with cognitive outcomes. A meta-analysis in 2016 integrat-
ing data from one randomized controlled trial and four observational studies did 
not find sufficient evidence supporting an association of anticoagulant treatment 
with lower dementia incidence among AF patients.[112] In contrast, a recent 
Swedish register-based retrospective study including all AF patients in Sweden 
from 2006 to 2014 reported a 29% lower risk of incident dementia among patients 
using anticoagulant drugs compared to those not on anticoagulant treatment.[113] 
The inconsistent findings across studies could be due to substantial methodologi-
cal variations; many studies suffer from high risk of bias including insufficient 
assessments of AF and cognitive endpoints, a short follow-up period, and high 
attrition rates.[112] Another challenge is that unlike cardiovascular outcomes such 
as stroke, the onset time of dementia is usually unclear due to its insidious onset 
and many people with dementia can remain undiagnosed for many years.[114] 
Therefore, evidence from longitudinal population-based studies is needed where 
AF, cognitive outcomes, and other health conditions are repeatedly assessed over 
time using comprehensive diagnostic tools. 
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1.4.3 Cerebral small vessel disease as a potential mechanism
Several potential pathways linking AF to cognitive decline and dementia have 
been suggested. Cerebral hypoperfusion due to reduced cardiac output and cerebral 
thromboembolism resulting from pro-thrombotic and pro-inflammation state have 
been considered as the main AF-related cerebrovascular consequences, which can 
further lead to structure brain abnormalities manifested as cerebral small vessel 
disease (SVD).[90,115–117] 
Cerebral SVD encompasses a group of pathological processes that affect brain 
small vessels including arterioles, small arteries, capillaries, and venules.[118,119] 
Features of cerebral SVD detected on neuroimaging devices such as magnetic reso-
nance imaging (MRI) include cerebral infarcts, lacunes, enlarged perivascular spaces 
(PVS), white matter hyperintensities (WMH), and brain atrophy.[119] Importantly, 
cerebral SVD is a leading cause of all-cause dementia, and vascular and mixed 
dementia in particular,[120] and has been hypothesized as a potential mechanism 
linking AF to cognitive decline and dementia.[121] Despite the potential adverse 
effect AF imposes on the brain, very few longitudinal population-based studies 
have examined the association between AF and various cerebral SVD markers.
Cerebral infarcts. Extensive evidence has suggested a strong association between 
AF and cerebral infarcts.[122,123] While cerebral infarcts manifested as overt 
strokes are the most feared consequences of AF, silent cerebral infarcts (SCIs) 
are far more common than clinical stroke and were found in up to 90% of people 
with AF in small case series.[121] A meta-analysis of eleven studies found that 
AF was associated with an increased odds of SCIs, regardless of AF subtypes.
[124] More recently, the ARIC study including 935 stroke-free middle-aged adults 
found that incident AF was associated with faster annual decline in word fluency 
only among people with prevalent SCIs; among people without prevalent SCIs, no 
association between incident AF and cognitive decline were found.[125] Another 
study including 1737 well-anticoagulated AF patients showed that the presence 
of SCIs have similar impact on cognitive function as clinical stroke.[123] These 
results suggested that the link between AF and cognitive deterioration might be 
partly explained by the presence or development of SCIs. 
Lacunes and visible perivascular spaces (PVS). Lacunes are defined as round 
fluid-filled cavities that are between 3 and 15 mm in diameter, and PVS are defined 
as fluid-filled spaces between a vessel and the basal membrane of the glia limi-
tans with a diameter often smaller than 3 mm; both lacunes and PVS have signals 
similar to that of cerebrospinal fluid.[119] While the underlying pathogenesis of 
lacunes and PVS have not been fully elucidated, current views suggest that both 
arise from vascular pathologies and are associated with several vascular risk fac-
tors. For instance, the ARIC study of 1827 individuals aged ≥55 years showed 
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that hypertension, diabetes, and ever smoking were significantly associated with 
the presence of lacunes.[126] A meta-analysis of 23 studies found that both hyper-
tension and lacunes were risk factors for the presence of PVS.[127] Despite that 
lacunes and PVS might be of vascular origin, population-based studies have rarely 
investigated the association between AF and these two cerebral SVD markers. 
White matter hyperintensities (WMH). Defined as hyperintense areas on 
T2-weighted or FLAIR images on MRI, WMH reflect a process of axonal loss and 
demyelination due to chronic cerebral ischemia. Clear evidence has shown that 
WMH predict increased risk of stroke and mortality, and that WMH are considered 
as one of the primary pathologies in vascular dementia.[128,129] Existing evidence 
for the association between AF and WMH mostly comes from cross-sectional 
studies, in which findings are not fully consistent. For example, pooled data from 
two population-based studies showed that AF was associated with periventricular 
WMH but not subcortical WMH,[130] while the ARIC study showed no significant 
association between AF and WMH after adjusting for vascular disease burden.
[131] So far, evidence from population-based studies that supports a longitudinal 
association between AF and WMH is lacking. 
Brain atrophy. Evidence regarding the association between AF and global 
and regional brain volumes are mixed. The Icelandic population-based AGES-
Reykjavik Study showed that people with AF had lower total brain tissue, gray 
matter, and white matter volumes compare to those without AF; these associa-
tions were more profound among patients with persistent or permanent AF than 
those with paroxysmal AF, indicating a potential cumulative effect.[132] In the 
cross-sectional analyses of the Framingham Offspring study, AF was significantly 
associated with lower frontal brain volume even controlling for vascular burden 
and APOE ε4 status; however, this association was not statistically significant in 
the longitudinal analyses.[133] Notably, a cross-sectional study of 122 stroke-free 
AF patients (mean age 60 years) and 563 controls (mean age 64 years) showed that 
AF was associated with lower hippocampal volume but not total brain tissue and 
WMH volume after adjusting for vascular disorders and their treatment.[134,135] 
1.5 Knowledge gaps
Findings from previous studies have collectively indicated important knowledge 
gaps regarding the temporal trend and its determinants in the incidence of dementia, 
as well as the role of AF in cognitive phenotypes and brain aging among older adults. 
First, while some reports have demonstrated a declining dementia incidence in 
high-income countries, there is still a lack of direct evidence from population-based 
cohorts in Sweden regarding the temporal trends in the incidence of dementia. 
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Moreover, it is still unclear whether and to what extent changes in a variety of 
risk (e.g., vascular disorders) and protective (e.g., cognitive reserve) factors for 
dementia over time can explain the declining incidence.  
Second, available estimates of AF prevalence mostly come from health adminis-
trative data and vary substantially across studies, and population-based studies are 
needed to estimate the age-specific prevalence of AF in the general older popula-
tion. In addition, few population-based studies have examined the patterns and 
temporal trends of use of antithrombotic drugs among older people with AF using 
both stroke and bleeding risk scores. 
Third, despite an established relationship between AF and a greater risk of demen-
tia among stroke patients, longitudinal population-based studies are needed to 
clarify whether AF is associated with cognitive decline and dementia in the gen-
eral older population regardless of clinical stroke. Furthermore, whether the use 
of anticoagulant drugs among older adults with AF reduces the risk of dementia 
remains unclear. 
Finally, while clinical and silent cerebrovascular lesions have been proposed as 
an important mechanism linking AF to cognitive decline and dementia, few pop-
ulation-based studies have investigated the association of AF with a spectrum of 
cerebral SVD markers on MRI, such as lacunes, PVS, WMH, and brain atrophy. 
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2 AIMS
Hypothesis
This doctoral thesis is based on the following hypotheses: (i) the incidence of 
dementia has declined in the older population in central Stockholm from the 1980s 
to the 2010s, and risk and protective factors experienced over the life-course, such 
as early-life educational achievements, midlife health behaviors and cardiometa-
bolic factors, as well as late-life cardiovascular disorders, may partly contribute to 
the decline; (ii) AF is associated with accelerated cognitive decline and a greater 
risk of dementia among older adults independent of clinical stroke and use of anti-
coagulant drugs is associated with a lower dementia risk among people with AF; 
and (iii) AF has an adverse impact on structural brain abnormalities manifested as 
cerebral SVD (e.g., WMHs, silent cerebral infarcts, and brain atrophy). 
Overall aim
The overall aim of this thesis is to better understand the temporal trend and its 
determinants in the incidence of dementia and the associations of AF with accel-
erated cognitive and brain aging among older adults. 
Specific aims
The following specific aims are addressed in the four individual studies included 
in the thesis:
i) To examine the temporal trend in dementia incidence in an older Swedish 
urban population from 1987 to 2013, and further, to identify factors that 
could partially explain such trend (Study I);
ii) To describe the prevalence of AF in the general older population and the 
patterns of use of antithrombotic medications in older adults with AF taking 
into account both stroke and bleeding risks (Study II);
iii) To investigate the longitudinal association of AF with cognitive decline and 
dementia among older adults, and to examine whether the use of anticoagu-
lant drugs is associated with a lower risk of dementia among people with AF 
(Study III);
iv) To investigate the association of AF with various cerebral SVD  
markers in older people (Study IV).
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3 MATERIALS AND METHODS
This doctoral thesis is based on data from the Kungsholmen Project (KP), the 
Swedish National study on Aging and Care in Kungsholmen (SNAC-K) popula-
tion study, and the SNAC-K MRI study. 
3.1 Population-based datasets
The Kungsholmen Project. KP is a longitudinal population-based study of 
aging and dementia.[136] On 1 October 1987, all 2368 residents, who were aged 
75 years and older, living in institutions or at home in the Kungsholmen district 
of central Stockholm, were invited to attend the 2-phase designed survey at base-
line (1987-1989), and 1810 (76.4%) people eventually participated. The baseline 
survey included a screening phase (phase I) where all participants undertook a 
Mini-Mental State Examination (MMSE) test, followed by a clinical phase (phase 
II) for people with an MMSE score ≤23 and a random sample of those with an 
MMSE score >23. Participants were then followed up every three years and data 
from 1987-1989 to 1997-1998 were used for the analysis of dementia incidence 
in Study I. Figure 2 shows the study population of KP.   
Figure 2. The study population and assessment waves of the Kungsholmen Project, 
1987-1989 to 1997-1998. D=dead; NP=non-participants; MMSE=Mini-Mental State 
Examination
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The SNAC-K population study. The SNAC-K study is a longitudinal population-
based cohort of older adults aged 60 years and older who were living in institutions 
or at home in the Kungsholmen district of Stockholm.[137] At baseline, the target 
general population was divided into eleven age cohorts with a six-year interval in 
the younger cohorts (60, 66, and 72 years) and a three-year interval in the older 
cohorts (78, 81, 84, 87, 90, 93, 96, and ≥99 years), from which random samples 
were drawn from each of these age cohorts. A total of 4590 alive and eligible peo-
ple were invited to participate and 3363 persons (response rate 73.3%) eventually 
took part in the baseline examination (2001-2004). Participants were then invited 
to follow-up examinations after six years for the younger cohorts  (re-examined in 
2007-2010) and every three years for the older cohorts (re-examined in  2004-2007, 
2007-2010, and 2010-2013). Figure 3 shows the study population of the SNAC-K 
project.
Figure 3. The study population and assessment waves of the SNAC-K study, 2001-2004 
to 2010-2013. B=baseline; F1=1st follow-up; F2=2nd follow-up; F3=3rd follow-up; D=dead; 
NP=non-participants
The SNAC-K MRI study. During September 2001 to October 2003, SNAC-K 
participants who were non-institutionalized, non-disabled, and free of dementia 
were invited to undertake a structural brain MRI examination, and 555 individuals 
were scanned at baseline. Participants were invited to follow-up MRI examinations 
after six years (re-examined in 2007-2010) for the younger cohorts and every three 
years for the older cohorts (re-examined in 2004-2007 and 2007-2010).
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3.2 Analytical samples 
Figure 4 shows the flowchart of study samples included in each of the four indi-
vidual studies. In Study I, 1473 dementia-free participants from the KP and 1746 
from the SNAC-K who were aged ≥75 years were included in the analyses of 
dementia incidence. In Study II, all 3363 baseline participants from the SNAC-K 
study were included for the estimation of AF prevalence at baseline. In study III, a 
total of 2685 dementia-free SNAC-K participants were included for the association 
of AF with incident dementia. Study IV included 540 participants in the SNAC-K 
MRI study for the cross-sectional analyses at baseline and 248 participants for the 
longitudinal analyses over the follow-up. 
Figure 4. Flowchart of the study populations included in Study I-IV. The figure shows 
number of participants at baseline, people excluded from the analyses (in perforated 
boxes), and the final analytical samples. 
3.3 Data collection and assessments
The KP and SNAC-K study followed similar protocols for data collection. Data 
were collected at baseline and follow-ups through clinical examinations, face-
to-face interviews, and laboratory tests in accordance with standard procedures. 
Information on demographic characteristics (age, sex, and education), lifestyle 
factors (e.g., alcohol consumption, smoking habit, and physical exercise), chronic 
medical conditions (e.g., diabetes, hypertension, coronary heart disease, and heart 
failure), use of medications, and cognitive function were collected by nurses, 
physicians, and psychologists. For each study examination, physicians performed 
a comprehensive review of participants’ health status based on results from the 
clinical examination, medical charts, self-reports, and information from proxies. 
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ICD-10 codes (International Classification of Diseases, Tenth Revision) were 
used to document diseases identified by the examining physicians. Data from 
the Swedish National Patient Register and Death Certificates were also linked to 
the SNAC-K and KP datasets to detect diseases before the baseline examination 
and during the follow-up period. During each study examination, participants 
were asked to bring their medication containers, and information on medication 
use at the time of visit were collected by the examining physicians and recorded 
according to the Anatomical Therapeutic Chemical (ATC) Classification System. 
Peripheral blood samples were taken, and genetic polymorphisms (e.g., APOE 
genotypes), total cholesterol, and glycated hemoglobin were examined at the 
university’s laboratory.
3.3.1 Ascertainment of atrial fibrillation 
AF was defined as a cardiac arrhythmia with the following characteristics on ECG: 
(i) irregular RR interval, (ii) no distinct P wave, and (iii) the interval between two 
atrial activations (when visible) is usually variable and <200 ms.[56]
In all studies included in this thesis, we identified AF cases through ECG and 
physician’s diagnosis (ICD-10 code I48) at each study visit. Medical records from 
the patient registers (I48) were also used to detect the presence and the onset date 
of AF prior to the baseline examination as well as during the follow-up period. 
Since AF is a chronic disease, once AF is identified, participants were considered 
to have AF throughout the study period. In Study II, people with AF at baseline 
were considered to have prevalent AF, while people who developed new AF during 
the follow-up before the diagnosis of dementia, death, or end of follow-up were 
considered to have incident AF. We defined the onset date of AF as the time of 
first AF diagnosis identified either during study visits or through register records, 
whichever came first. 
3.3.2 Stroke and bleeding scores
In SNAC-K, CHADS2 score and CHA2DS2-VASc score were calculated to assess 
the risk of stroke among participants with AF. The CHADS2 score ranges from 
0 to 6 and consists of heart failure, hypertension, age ≥75 years, diabetes, and 
ischemic stroke/TIA (double points). The CHA2DS2-VASc score ranges from 0 
to 9 and consists of heart failure, hypertension, age ≥75 years (double points), 
diabetes, ischemic stroke/TIA (double points), female sex, and vascular diseases 
(i.e., peripheral arterial diseases or myocardial infarction).[57] For both CHADS2 
and CHA2DS2-VASc, a score ≥2 indicates high stroke risk. 
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HAS-BLED score was used to assess the risk of bleeding.[138] Since data on labile 
INR is not available in the SNAC-K dataset, an incomplete HAS-BLED score 
was calculated: hypertension, abnormal renal function, abnormal liver function, 
ischemic stroke/TIA, major bleeding, age ≥65 years, excessive alcohol consump-
tion, and use of medications including anti-platelet drugs (ATC code: B01AC) 
and nonsteroidal anti-inflammatory drugs (M01A and N02BA). The incomplete 
HAS-BLED score therefore ranges from 0 to 8, and a score ≥3 indicates high risk 
of major bleeding [6]. 
3.3.3 Assessment of study outcomes 
Cognitive function and dementia 
In both KP and SNAC-K, global cognitive function was measured using MMSE 
at each study examination. 
For the diagnosis of dementia, a two-phase procedure was used to identify dementia 
cases at KP baseline [19]. In Phase 1 (the screening phase), all participants were 
screened using MMSE; in Phase 2 (the clinical phase), people who had an MMSE 
score <24 and a random sample of those who had an MMSE score ≥24 under-
went comprehensive clinical examinations, cognitive tests, and laboratory tests. 
During the follow-up examinations of KP, all participants were directly examined 
instead. Dementia diagnosis was made according to the Diagnostic and Statistical 
Manual of Mental Disorders, 3rd edition, revised (DSM-III-R) criteria following a 
validated 3-step procedure: the examining physician made a preliminary diagno-
sis of dementia based on the face-to-face interviews, clinical examinations, and 
cognitive tests; then a second physician independently made another preliminary 
diagnosis. In case of disagreement between the first two diagnoses, a third opinion 
was sought from a senior physician.[139] 
In SNAC-K, all participants were examined using structured interviews, clinical 
examinations, and cognitive testing at each study examination. The same 3-step 
procedure as in KP was adopted in SNAC-K for the diagnosis of dementia fol-
lowing the DSM-IV criteria. Vascular dementia was diagnosed following the 
NINDS-AIREN (National Institute of Neurological Disorders and Stroke and 
Association Internationale pour la Recherch´e et l’Enseignement en Neurosciences) 
criteria,[140] and AD was diagnosed in accordance with the NINCDS-ADRDA 
(National Institute of Neurological and Communicative Disorders and Stroke and 
the Alzheimer’s Disease and Related Disorders Association) criteria.[141] Because 
dementia cases are often caused by mixed pathologies of both cerebrovascular 
injuries and neurodegeneration,[142] participants who had a concurrent diagnosis 
of vascular dementia and AD were considered to have mixed dementia.
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In both KP and SNAC-K, medical records for all participants and death certificates 
for participants who died during the follow-up were collected and reviewed by 
physicians to determine whether the participants died with dementia.
MRI markers for cerebral SVD
MRI protocol. In SNAC-K MRI study, eligible participants were scanned on 
a Philip Intera 1.5T MR scanner (Eindhoven, The Netherlands) at baseline and 
follow-ups. The protocol included a three-dimensional T1-weighted fast field echo 
(repetition time [TR] 15 ms, echo time [TE] 7 ms, flip angle [FA] 15°, field of 
view [FOV] 240, 128 slices with slice thickness 1.5 mm and in-plane resolution 
 0.94 × 0.94 mm, no gap, matrix 256×256), and an axial turbo fluid-attenuated 
inversion recovery sequence (FLAIR; TR 6000 ms, TE 100 ms, inversion time 
1900 ms, FA 90°, echo train length 21, FOV 230, 22 slices with slice thickness 
5 mm and in-plane resolution 0.90 × 0.90 mm, gap 1 mm, matrix 256 × 256).[143]
Assessment of cerebral SVD markers. MRI markers of cerebral SVD included 
cerebral infarcts, lacunes, PVS, WMH, and brain volumes (e.g., global brain  tissue 
volume and lateral ventricular volume). Cerebral infarcts, lacunes, and PVS were 
visually assessed by an experienced clinical neuroradiologist. Lacunes were identi-
fied on FLAIR images. PVS were identified in different brain regions  (e.g., fron-
tal lobe, hippocampus, basal ganglia, cerebellum, and parieto-occipital lobe) on 
T1, T2, and FLARE images. A second radiologist reviewed the MRI images of 
18 subjects for PVS and this evaluation yielded a weighted κ of 0.77 (inter-rater 
reliability).[144] The number of PVS in all brain regions were then summed up 
and categorized into ≥10 and <10.[145]
T1-weighted images were automatically segmented into gray matter, white  matter, 
and CSF using the improved unified segmentation algorithm in the SPM12 in 
MATLAB 10 (MathWorks Inc., MA, USA).[146] A specialist in neuroimag-
ing analysis visually inspected all segmentations. Total brain tissue volume was 
calculated by adding gray matter and white matter volume. Lateral ventricular 
volumes were automatically segmented and estimated using the ALVIN toolbox, 
and were further visually verified for accuracy.[147] FreeSurfer image-analysis 
suite software version 5.1 was used to automatically segment the left and right 
hippocampi and calculate their volumes.[148] Global WMH volumes were manu-
ally drawn by a single rater on FLAIR images and were further interpolated on 
the corresponding T1 images to compensate for the gap between slices on FLAIR 
(mean Dice coefficient = 0.76).[149] All volumetric measurements were corrected 
using total intracranial volume.
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3.3.4 Assessment of covariates
Demographic factors
Information on age, sex, and education of the participants was collected through 
baseline interviews. Education was assessed as highest attained level of formal 
education.
Lifestyle factors
Alcohol consumption was measured based on the frequency and amount of alcohol 
consumed on a typical drinking day, and was categorized as never or occasional, 
light/moderate, and heavy drinking. The Alcohol Use Disorders Identification Test 
(AUDIT) was also used to assess alcohol consumption, and an AUDIT score ≥8 
indicates excessive alcohol consumption. Smoking status was assessed by asking 
the participants whether they had ever smoked, for how long they had smoked, and 
the number of cigarettes per day. Participants were categorized as never, former, or 
current smokers. Physical exercise was assessed through self-administered ques-
tionnaires by asking the participants whether they were regularly engaged in light, 
moderate, or intense exercises, and categorized as inactive (light and/or intensive 
exercise ≤2–3 times per month) and active (light, moderate, or intensive exercise 
several times per week). Physical activity was assessed through self-administered 
questionnaires by asking the participants whether they were engaged in any leisure 
activities with physical components (e.g., walking, gardening, and going to the 
museum) over the past 12 months, and was categorized into inactive (<1 time per 
month) and active (≥1 time per month). 
Work complexity and psychosocial working condition
Information on job title, contents, employer, and time span of the longest-held jobs 
during adulthood was collected through a structured questionnaire.[150,151] Work 
complexity scores (i.e., with people, data, and things) for the longest-held job in 
adulthood were recorded according to a validated work complexity matrix, where 
higher scores indicate greater complexity [152]. Level of psychosocial working 
condition for the longest-held job during adulthood, including job control and job 
demand, was estimated using a validated job-exposure matrix [153]. Using the 
median score of job control and demands, participants were then categorized into 
four groups: high job strain (low control and high demands), low job strain (high 
control and low demands), passive job (low control and low demands), and active 
job (high control and high demands).
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Cardiovascular risk factors
Weight and height of the participants were measured with light clothes and no 
shoes. Body mass index (BMI) was calculated as weight in kilograms divided by 
height in meters squared. In a sitting position, the participants were fitted with 
a sphygmomanometer and arterial blood pressure was measured twice on the 
left arm with a 5-miniute interval; the average of the two values was used in the 
analysis. Diabetes was defined as having glycated hemoglobin >6.4%, having a 
diagnosis from the examining physicians during study visits or from the patient 
register records (ICD-10 codes: E10–E14), or using diabetes drugs (ATC code: 
A10). Hypertension was defined as blood pressure ≥140/90 mm Hg or use of 
antihypertensive drugs (ATC codes: C02, C03, C07, C08, and C09). Dyslipidemia 
was defined as having non-fasting total serum cholesterol ≥6.22 mmol/L or use 
of lipid-lowering drugs (ATC code: C10).
Chronic diseases
Heart failure, abnormal liver function, cerebrovascular disease, ischemic stroke/
transient ischemic attack (TIA), and major bleeding events (both gastrointestinal 
and intracranial) were identified through either physician’s diagnosis during study 
visits or from the patient register records using ICD-10 codes. Coronary heart 
disease was defined as having a diagnosis from the examining physicians during 
study visits or register records or current use of nitrates (ATC code: C01DA) or 
ranolazine (C01EB18).[154] Abnormal kidney function was defined as having a 
physician’s diagnosis at study visits or from register records, or having an esti-
mated glomerular filtration rate <60 mL/min/1.73 m2, which was calculated from 
the participants’ serum creatine level.[155] 
APOE genotype
APOE genotyping was performed using MALDI-TOF (matrix-assisted laser des-
orption/ionization time-of-flight) analysis on a modified Sequenom MassARRAY 
platform at the Mutation Analysis Facility, Karolinska Institutet. APOE genotype 
was grouped into carrying any ε4 allele vs. no ε4 allele. 
3.3.5 Statistical analysis
Stata Statistical Software 14 or 15 (StataCorp LLC, TX, USA) was used for all 
analyses. In all studies, baseline characteristics were compared using χ2 test for 
categorical variables and t-tests for continuous variables. The statistical signifi-
cance level was set at two-tailed test p<0.05. 
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Study I. For both the KP and SNAC-K cohorts, 10-year follow-up data since the 
baseline examination were analyzed: 1987-1989 to 1997-1998 for the KP cohort, 
and 2001-2004 to 2010-2013 for the SNAC-K cohort. Cox regression models were 
performed to compare the incidence rate of dementia in the SNAC-K cohort to that 
in the KP cohort. To explore to what extent the changes in dementia incidence rate 
were attributable to changes in dementia protective and risk factors, Cox regres-
sion models were adjusted for age, sex, education, lifestyle factors, work-related 
factors, and chronic health conditions in the two cohorts. 
Study II. At baseline, the age- and sex-specific prevalence of AF was estimated. 
Proportions of use of antithrombotic drugs (ATC codes: B01AA and B01AC) at 
baseline among participants with AF were calculated. To examine the temporal 
trend in the use of antithrombotic drugs, participants with AF who were aged over 
66 years at baseline (2001–2004) and 6-year follow-up (2007–2010) were included. 
Logistic regressions were used to compare the proportion of use of antithrombotic 
drugs between baseline and 6 years later.
Study III. We used linear mixed-effects models to assess the association of AF 
with rate of annual decline in global cognition over the 9-year follow-up period; 
Cox proportional hazard regressions were used to examine the association of AF 
with incident dementia. In all models, AF was treated as a time-varying exposure 
where both prevalent and incident AF cases were considered. In order to minimize 
the influence of clinical stroke/TIA on the association between AF and demen-
tia, we repeated the Cox regression models by excluding people with prevalent 
stroke/TIA diagnosis and censoring people at the dates when incident stroke/TIA 
occurred during the follow-up.    
Among people with either prevalent or incident AF, propensity score-weighted 
Cox regressions were used to examine the association between use of antithrom-
botic drugs and incident dementia. The propensity score method was adopted to 
balance the characteristics that could differ between drug users and nonusers (i.e., 
baseline age, sex, education, heart diseases, kidney disorders, and MMSE score, 
etc.).[156] Lastly, we used the population attributable risk to estimate the propor-
tion of dementia cases that could be hypothetically avoided if all AF patients had 
been in the treatment group.  
Study IV. Logistic regression models were used to examine the across-sectional 
association of AF with the presence of cerebral infarcts, the presence of lacunes, 
and number of PVS (≥10 vs. <10) on MRI at baseline. Linear mixed-effects models 
were performed to estimate the annual changes in MRI volumetric measurements 
over the follow-up period in association with AF.
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3.3.6 Ethical considerations
All phases of the KP and SNAC-K study as well as the linkage with patient registers 
and death certificates have been approved by the Ethics Committee at Karolinska 
Institutet and the Reginal Ethical Review Board in Stockholm, with the following 
registration numbers for KP: 87-148; 87-234 (Phases I & II), 90-251 (Phase III), 
94-122 (Phase IV), 99-308 (Phase V), 99-025 (death certificate), and 01-020 (patient 
register), and SNAC-K: 01-114 (baseline), 04-929/3 (1st follow-up), Ö26-2007 
(2nd follow-up), 2010/447-31/2 (3rd follow-up), and 2009/595-32 (register data).
Informed and written consent is collected from each and every participant of the 
KP and SNAC-K study; if the participant is severely cognitively impaired, the 
consent is given by a proxy (family members or guardians). During the examination 
process, the participants were assessed in a friendly and comfortable environment; 
if the participant expresses anguish or discomfort, the interview ends regardless of 
whether the participant or the proxy has given consent. The participants are also 
asked if they want to be informed of any disease detected during the examination, 
and in such cases, they are referred to their family doctors or other physicians. In 
addition, the participants are given feedback on the research conducted using the 
SNAC-K data, and this is done through various seminars held by researchers and 
booklets of scientific results.
All the data obtained from the participants become anonymous once they are 
digitalized from the questionnaires; this is done by giving each participant an 
artificial personal identification number, and all names and personnummer are 
removed. The original questionnaires are stored in locked safety cabins. All 
researchers working with the dataset respect and follow the ethical guidelines of 
the Swedish Council for Research in the Humanities and Social Sciences and the 
Ethical Principles for Medical Research Involving Human Subjects expressed in 
the Declaration of Helsinki.
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4 MAIN RESULTS
Below are brief summaries of the main results from each of the four individual 
studies included in this thesis. For more details on each study, please see the 
manuscripts and published articles at the end of the thesis. 
4.1 Temporal trend in the incidence of dementia (Study I) 
At baseline, a higher proportion of participants from the SNAC-K cohort than from 
the KP cohort never or occasionally consumed alcohol, had physical activities, 
were former smokers than current smokers, had active jobs, and had higher work 
complexity scores (age- and sex-adjusted p<0.05 for all). More people had diabetes 
and AF and less had hypertension in the SNAC-K cohort than in the KP cohort, 
while the proportions of participants with other cardiovascular or cerebrovascular 
conditions were not statistically different between the two cohorts.
Over the 10-year follow-up period, 440 (29.9%) out of 1473 participants in the 
KP cohort developed incident dementia from 1987-1989 to 1997-1998, and 387 
(22.2%) out of 1746 persons in the SNAC-K cohort developed incident dementia 
from 2001-2004 to 2010-2013. The crude incidence rate of dementia was virtually 
lower in the SNAC-K than in the KP cohort across all age groups except for the 
oldest-old (≥90 years), among both men and women, and in both education levels 
(elementary school vs. middle school or above) (Figure 5). 
A
B
 
Figure 5. Incidence rate of dementia per 1000 person-years (PY) in the KP and SNAC-K 
cohort, stratified by (A) age groups and birth cohorts and (B) sex and education levels.
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Cox regression models showed that the incidence rate of dementia was signifi-
cantly lower in the SNAC-K than in the KP cohort after adjusting for age and sex 
(HR=0.70; 95% CI, 0.61-0.80), corresponding to an annual reduction of 3.0% in 
dementia risk. Further adjusting for education, lifestyle factors, work-related fac-
tors, and chronic diseases did not substantially change the results  (HR=0.77, 95% 
CI: 0.65-0.90). In the stratified analyses, the incidence rate of dementia was sig-
nificantly lower in the SNAC-K cohort than in the KP cohort in all age groups 
after adjusting for age and sex, except for age group ≥90 years where the incidence 
was unchanged. A significant decline in the incidence rate of dementia was also 
seen among women (HR=0.71, 95% CI: 0.59-0.86) and in people with elementary 
education (HR=0.57, 95% CI: 0.43-0.75) (Table 4).
Table 4. Hazard ratio (95% confidence interval) for incident dementia comparing 
the SNAC-K cohort (2001-2013) to the KP cohort (1987-1998) in the total popula-
tion and stratified by age groups, sex, and education level
Hazard Ratio (95% CI) of dementia for SNAC-K vs. KP cohort
Characteristics Model 1a Model 2b Model 3c
Total population 0.70 (0.61-0.80)d 0.75 (0.65-0.87)d 0.77 (0.65-0.90)d
By age groups, years
75-79 0.70 (0.55-0.89)d 0.82 (0.64-1.06) 0.92 (0.69-1.22)
80-84 0.66 (0.52-0.85)d 0.72 (0.55-0.94)d 0.69 (0.50-0.94)d
85-89 0.65 (0.44-0.96)d 0.65 (0.44-0.99)d 0.59 (0.38-0.93)d
≥90 1.17 (0.78-1.77) 1.16 (0.76-1.76) 1.00 (0.62-1.60)
By sex
Men 0.82 (0.61-1.09) 0.88 (0.65-1.18) 0.94 (0.68-1.29)
Women 0.66 (0.56-0.77)d 0.71 (0.60-0.84)d 0.71 (0.59-0.86)d
By education level
Elementary school 0.56 (0.43-0.72)d 0.56 (0.43-0.72)d 0.57 (0.43-0.75)d
Middle school or above 0.89 (0.74-1.07) 0.89 (0.74-1.07) 1.01 (0.72-1.43)
Missing values in covariates are imputed using multiple imputation. aAdjusted for age and sex. 
bAdjusted for age, sex, and education. cAdjusted for age, sex, education, BMI, smoking, alcohol con-
sumption, physical activity, work complexity, psychosocial working condition, hypertension, diabetes, 
ischemic heart disease, heart failure, atrial fibrillation, and cerebrovascular diseases. dp<0.05.
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4.2 Prevalence of atrial fibrillation and use of antithrom-
botic Drugs (Study II) 
A total of 328 (9.8%) out of 3363 participants at SNAC-K baseline (2001-2004) 
were classified to have AF. Figure 6 shows the age- and sex-specific prevalence 
of AF, where the prevalence increased with advancing age, from 2.8% among 
people aged 60-66 years and 13.2% in those aged 81-87 years to 21.2% in people 
aged ≥90 years. The prevalence of AF was higher in men than in women in all 
age groups (age-adjusted OR=1.91, p<0.001).
Figure 6. Prevalence of atrial fibrillation by age and sex at SNAC-K baseline (2001-2004)
Among participants with AF at baseline (n=328), 79.6% were classified as hav-
ing high risk of stroke based on the CHADS2 score and 97.3% according to 
the CHA2DS2-VASc score. Among AF patients with intermediate risk of stroke 
(CHADS2=1), 17.0% were taking anticoagulant drugs and 39.6% were using 
antiplatelet drugs. Of people with CHADS2 score ≥2, 25.4% and 53.5% were 
taking anticoagulant drugs and antiplatelet drugs, respectively. Re-grouping the 
participants using the CHA2DS2-VASc score did not substantially change the pro-
portions of drug use in the high-risk group (Table 5). Of note, among AF patients 
with CHADS2 score ≥2 at baseline, having a HAS-BLED score ≥3 was associated 
with not using anticoagulant drugs (multi-adjusted OR=2.66, 95% CI: 1.08–6.53).
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Table 5. Use of anticoagulant and antiplatelet drugs among people with atrial fibrilla-
tion at baseline (2001-2004), stratified by levels of stroke and bleeding risk
Risk stratification No. of  AF 
cases
Anticoagulant drug use Antiplatelet drug use
n % (95% CI) n % (95% CI)
Total population 327 75 22.9 (18.4-27.5) 160 48.9 (43.5-54.3)
CHADS2 score
Low risk (0) 14 0 0.0 (0.0-0.0) 0 0.0 (0.0-0.0)
Intermediate risk (1) 53 9 17.0 (6.9-27.1) 21 39.6 (26.5-52.8)
High risk (2-6) 260 66 25.4 (20.1-30.7) 139 53.5 (47.4-59.5)
CHA2DS2-VASc score
Low risk (0) 3 0 0.0 (0.0-0.0) 0 0.0 (0.0-0.0)
Intermediate risk (1) 6 0 0.0 (0.0-0.0) 1 16.7 (0.4-64.1)
High risk (2-9) 318 75 23.6 (19.0-28.6) 159 50.0 (44.4-55.6)
HAS-BLED scorea
Low risk (0-2) 89 28 31.5 (21.8-41.1) 8 9.0 (3.0-14.9)
High risk (3-8) 238 47 19.7 (14.7-24.8) 152 63.9 (57.8-70.0)
aThe HAS-BLED score does not include labile INR. 
Over the six-year follow-up period (2001-2004 to 2007-2010), the proportion 
of use of anticoagulating drugs significantly increased among AF patients with 
CHA2DS2-VASc score ≥2 (23.0% vs. 33.1%, p=0.008), and among those who had 
a HAS-BLED score <3 (32.0% vs. 52.5%, p=0.004). No significant change was 
observed in the use of antiplatelet drugs among participants with AF during this 
period (49.5% vs. 45.8%, p=0.423) (Table 6).
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Table 6. Use of anticoagulant and antiplatelet drugs among people with atrial fibrilla-
tion in 2001-2004 and 2007-2010, respectively
Risk stratification Year 2001-2004 Year 2007-2010 pb
N/na % (95% CI) N/na % (95% CI)
Use of anticoagulant drugs
Total (age ≥66 years) 313/71 22.7 (18.0-27.3) 308/101 32.8 (27.5-38.0) 0.005
CHADS2 score
Low risk (0) 10/0 0.0 (0.0-0.0) 5/1 20.0 (0.0-55.1) -
Intermediate risk (1) 48/8 16.7 (6.1-27.2) 37/9 24.3 (10.5-38.1) 0.313
High risk (2-6) 255/63 24.7 (19.4-30.0) 266/91 34.2 (28.5-39.9) 0.085
CHA2DS2-VASc score
Low risk (0) 0/0 0.0 (0.0-0.0) 0/0 0.0 (0.0-0.0) -
Intermediate risk (1) 4/0 0.0 (0.0-0.0) 3/0 0.0 (0.0-0.0) -
High risk (2-9) 309/71 23.0 (18.4-28.1) 305/101 33.1 (27.9-38.7) 0.008
HAS-BLED scorec
Low risk (0-2) 75/24 32.0 (21.4-42.6) 59/31 52.5 (39.8-65.3) 0.004
High risk (3-8) 238/47 19.7 (14.7-24.8) 249/70 28.1 (22.5-33.7) 0.073
Use of antiplatelet drugs
Total (age ≥66 years) 313/155 49.5 (44.0-55.1) 308/141 45.8 (40.2-51.3) 0.423
CHADS2 score
Low risk (0) 10/0 0.0 (0.0-0.0) 5/1 20.0 (0.0-55.1) -
Intermediate risk (1) 48/17 35.4 (21.9-48.9) 37/13 35.1 (19.8-50.5) 0.853
High risk (2-6) 255/138 54.1 (48.0-60.2) 266/127 47.7 (41.7-53.7) 0.374
CHA2DS2-VASc score
Low risk (0) 0/0 0.0 (0.0-0.0) 0/0 0.0 (0.0-0.0) -
Intermediate risk (1) 4/0 0.0 (0.0-0.0) 3/0 0.0 (0.0-0.0) -
High risk (2-9) 309/155 50.2 (44.4-55.9) 305/141 46.2 (40.5-52.0) 0.400
HAS-BLED scorec
Low risk (0-2) 75/3 4.0 (0.0-8.4) 59/5 8.5 (1.4-15.6) 0.911
High risk (3-8) 238/152 63.9 (57.8-70.0) 249/136 54.6 (48.4-60.8) 0.066
aN/n = number of patients with atrial fibrillation/number of patients who used drugs. bAdjusted for age, 
sex, and education. cThe HAS-BLED score does not include labile INR.  
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4.3 Association of atrial fibrillation with cognitive 
decline and dementia (Study III)
Of the 2685 dementia-free participants at baseline, 243 (9.1%) were classified as 
having AF. Over the 9-year follow-up period (mean per person 5.8 years, SD 2.2 
years), 279 (11.4%) out of the 2442 AF-free older adults were detected to have 
incident AF. A total of 399 (14.9%) incident dementia cases were identified includ-
ing 116 (6.2%) people with AD and 68 (2.5%) with vascular or mixed dementia. 
Over the 9-year follow-up period, AF, as a time-varying variable, was significantly 
associated with a faster annual decline in MMSE score controlling for baseline 
demographic factors, lifestyle factors, cardiometabolic conditions, and cardiovas-
cular diseases (β coefficient = -0.24, 95% CI: -0.31, -0.16) (Figure 7). 
Figure 7. Average decline in the MMSE score by atrial fibrillation status from linear 
mixed-effects model. The model is adjusted for age, sex, education, excessive alcohol 
consumption, ever smoking, physical exercise, body mass index, hypertension, diabe-
tes, dyslipidemia, coronary heart disease, and heart failure.
Multi-adjusted Cox regression models showed that, as a time-varying variable, AF was 
significantly associated with an elevated dementia risk (HR=1.40, 95% CI: 1.11-1.77). 
In the stratified analyses, the association between AF and dementia was statistically 
evident only among women and in APOE ε4 carriers (Figure 8). Excluding people 
with prevalent stroke/TIA (n=114) and censoring people at the dates when incident 
stroke/TIA occurred (n=72) did not substantially change the estimates.
With regard to dementia subtypes, AF was significantly associated with an greater 
risk of vascular and mixed dementia combined (HR=1.88, 95% CI: 1.09-3.23); this 
association was particularly evident among APOE ε4 allele carriers (HR=5.78, 95% 
CI: 1.26-26.50). The association of AF with risk of AD was not statistically sig-
nificant (HR=1.33, 95% CI: 0.92-1.94) (Table 7).
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Figure 8. Hazard ratios and 95% confidence intervals (CI) of incident all-cause dementia 
associated with atrial fibrillation (AF) in the total sample and by sex and APOE geno-
type. Models are adjusted for age, sex, education, ever smoking, excessive alcohol 
consumption, physical exercise, body mass index, diabetes, hypertension, dyslipidemia, 
coronary heart disease, and heart failure.
Among participants with either prevalent or incident AF, propensity score-weighted 
Cox regression models showed a significant association between the use of antico-
agulant drugs and a reduced risk of incident dementia over a 6-year follow-up period 
(HR=0.40, 95% CI: 0.18-0.92); the use of antiplatelet drugs was non-significantly 
associated with a higher dementia risk (HR=1.84, 95% CI: 0.99-0.42) (Table 8). 
Under the assumption of a causal association between anticoagulant therapy and 
a lower dementia risk, we estimated that around 54% of all dementia cases would 
have been hypothetically avoided if all participants with AF had received antico-
agulant drugs (population attributable risk=0.46, 95% CI: 0.22-0.95).
Table 8. Hazard ratios (95% confidence intervals) of dementia associated with use 
of anticoagulant and antiplatelet drugs among participants with either prevalent or 
incident atrial fibrillation (n=470)
Antithrombotic drugsa No. of participants No. of dementia 
cases
Hazard ratio (95% confidence 
interval)b
Anticoagulant drugs
Non-users 342 76 1.00 (Reference)
Users 128 14 0.40 (0.18-0.92)c
Antiplatelet drugs
Non-users 187 25 1.00 (Reference)
Users 283 65 1.84 (0.99-3.42)d
aTreated as a time-varying variable.  bWeighted by propensity score, and additionally adjusted for ever 
smoking, physical exercise, dyslipidemia, and body mass index.  cp=0.031, dp=0.055.
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4.4 Association of atrial fibrillation with cerebral SVD 
markers (Study IV)
The mean age of the 540 participants in SNAC-K who underwent MRI examina-
tions at baseline was 70.8 years (SD 9.1), 58.5% were women, and 40.4% obtained 
a university degree. A total of 39 (7.2%) participants were identified to have AF 
at baseline.
Logistic regression analysis showed that AF at baseline was significantly associated 
with an increased odds ratio (OR) of having cerebral infarcts on MRI (OR=3.98, 
95% CI: 1.31-12.09) after adjusting for demographic factors, lifestyle factors, and 
chronic diseases. There was no significant association of AF with lacunes (OR=1.01, 
95% CI: 0.33-3.08) and enlarged PVS (OR=5.71, 95% CI: 0.65-50.15) (Table 9).
Table 9. Cross-sectional associations of atrial fibrillation with cerebral infarcts, lacu-
nes, and enlarged perivascular spaces at baseline (2001-2004) 
MRI measures (as outcomes) No. of 
subjects
No. of 
cases
Odds ratio (95% confidence interval)
Model 1a Model 2b
Cerebral infarcts (yes vs. no)
AF, absent 501 21 1.00 (reference) 1.00 (reference)
AF, present 39 8 4.49 (1.69-11.96) 3.98 (1.31-12.09)
Lacunes (yes vs. no)
AF, absent 501 45 1.00 (reference) 1.00 (reference)
AF, present 39 5 1.20 (0.43, 3.30) 1.01 (0.33, 3.08)
Perivascular spaces (≥10 vs. <10)
AF, absent 501 462 1.00 (reference) 1.00 (reference)
AF, present 39 36 2.68 (0.35, 20.69) 5.71 (0.65, 50.15)
aModel 1 was adjusted for age, sex, and education. bModel 2 was additionally adjusted for current 
smoking, alcohol consumption, physical exercise, body mass index, hypertension, diabetes, dyslipi-
demia, heart failure, and coronary heart disease. 
In the analysis of longitudinal associations of baseline AF with alterations of 
cerebral SVD markers over the follow-up period, 248 participants who were free 
of cerebral infarcts on MRI at both baseline and follow-ups were included. Over 
the 6-year follow-up period, linear mixed-effects models showed that, as a time-
varying variable, AF was significantly associated with a faster annual increase 
in WMH volume (β coefficient=0.45, 95% CI: 0.04, 0.85) and lateral ventricular 
volume (β coefficient=0.57, 95% CI: 0.13, 1.02) after controlling for demographic 
factors, lifestyle factors, and chronic diseases (Figure 9). AF was associated with 
an annual decline in total brain tissue volume, but the association was not statisti-
cally significant (β coefficient=-1.17, 95% CI: -3.68, 1.34). 
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A B
Figure 9. Average annual changes in (A) white matter hyperintensity (WMH) volume 
and (B) lateral ventricular volume from linear mixed-effects models, stratified by atrial 
fibrillation (AF) status. Models were adjusted for age, sex, education, current smoking, 
alcohol consumption, physical exercise, body mass index, hypertension, diabetes, dys-
lipidemia, heart failure, and coronary heart disease.
38
5 DISCUSSION
5.1 Summary of main findings
In this doctoral thesis, we investigated the temporal trend in the incidence of 
dementia from the late 1980s to the early 2010s in an urban Swedish population 
and further explored to what extent changes in a range of protective and risk fac-
tors for dementia could explain the temporal trend. Furthermore, we estimated the 
prevalence of AF in a general older population and examined the temporal trend 
in the use of antithrombotic drugs among older adults with AF. Moreover, we 
investigated the longitudinal association of AF with cognitive decline and risk of 
dementia, the cognitive benefits of anticoagulant drugs among people with AF, as 
well as the relationship between AF and various cerebral SVD markers detected on 
brain MRI. The main findings from this doctoral thesis are summarized as follows:
i) The incidence of dementia had declined from the late 1980s to the early 
2010s in central Stockholm, Sweden, especially among women and in 
people with low education. Improvement in lifestyle, cardiovascular health, 
and cognitive reserve could only explain a small part of the decreasing trend 
in dementia risk (Study I).
ii) AF is common in people aged 60 years and older. The use of anticoagulant 
drugs among older people with AF increased from 2001-2004 to 2007-2010, 
especially in those with high risk of stroke or low risk of bleeding. However, 
still two-thirds of those with high risk of stroke remained untreated with 
anticoagulant drugs (Study II). 
iii) AF is associated with an accelerated cognitive decline and a greater risk of 
all-cause dementia, especially vascular and mixed dementia, among older 
adults. The use of anticoagulant drugs, but not antiplatelets, is associated 
with a lower risk of incident dementia in older people with AF (Study III). 
iv) Among older adults, AF is correlated with the presence of cerebral infarcts 
and associated with an accelerated increase in WMH volume and lateral 
ventricular volume in the absence of cerebral infarcts (Study IV). 
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5.2 The declining incidence of dementia
Study I showed direct evidence from two population-based cohorts that the incidence 
of dementia has declined in central Stockholm, Sweden. This is in line with an ear-
lier Swedish study which inferred a decline in the incidence of dementia based on a 
relatively stable prevalence of dementia and a prolonged survival among dementia 
patients.[29] As described in the introduction section of this thesis, a declining 
incidence of dementia has been reported from population-based cohorts in Europe 
and North America such as the UK,[12,13] the Netherlands,[14] France,[15] and the 
USA.[16–18] In addition, a recent systematic review and meta-analysis integrat-
ing data from five population-based studies in Western high-income countries has 
suggested a favorable trend in dementia incidence.[157] When stratified by educa-
tion level, a much greater decline in dementia incidence was seen among people 
with at most eight years of formal education (i.e., elementary school) than those 
with more education in our study. Only two US studies have examined dementia 
trends in different education groups, but showed a more evident decline among 
people with higher education.[17,18] However, it is difficult to directly compare 
the education levels between American and European populations since they were 
categorized and reported differently among studies. Beyond Western countries, 
investigations from Asian populations such as Japan[20] and China[158] have 
suggested an increasing incidence of dementia, although the increasing trends 
might be partly attributable to the great heterogeneity in study methodologies.[9] 
Factors underlying the observed decreasing trends in dementia incidence in high-
income countries are not entirely clear. Several hypotheses have been proposed, 
such as improved education, better management of major cardiovascular risk fac-
tors, and improvement in prevention of cardiovascular events over time,[159,160] 
which could lead to a compression of cognitive morbidity in old ages, manifested 
as delayed dementia onset and shorter disease duration in people with dementia.
[161,162] Indeed, the education pattern has considerably changed over time in our 
study, with 78% of the SNAC-K population (2001-2004) having education above 
elementary level compared to only 49% in the KP cohort (1987-1989). In addition, 
work complexity and the proportion of people with active jobs were also substan-
tially higher in the SNAC-K population. This rising level of formal education and 
improved psychosocial working conditions could have led to an increased stock 
of cerebral and cognitive reserve.[163] However, our study showed that account-
ing for the changes in various dementia protective and risk factors, including 
improved lifestyle, cardiovascular health, and cognitive reserve, over a period of 
two decades could only explain a small part of the observed decline in dementia 
incidence. This is consistent with previous findings from the Framingham Heart 
Study that the dropping dementia incidence could not be explained by improved 
education level and decreasing prevalence of vascular risk factors and cardiovascu-
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lar diseases over the study period.[17] Nevertheless, our findings do not rule out a 
role for the examined dementia-related factors in explaining the decreasing trends, 
however, the role of other unexplored factors over the lifespan such as early life 
living conditions, leisure time activities during midlife, psychological stress, and 
exposure to toxic substance such as air pollution, warrants further investigations. 
5.3 Prevalence of atrial fibrillation and use of antithrom-
botic drugs 
Findings from Study II showed that the prevalence of AF among older adults from 
the general population appears to be slightly higher than previously reported. 
For example, the prevalence of AF in our study was 11% among people aged 
72-78 years compared to a range of 3-10% in previous reports.[41,43,44] We 
reported a prevalence of 21% in people aged 90 years and above compared to a 
range of 10-17% in other studies.[40,43,45] As described in the introduction sec-
tion of this thesis, discrepancies in the prevalence of AF among previous studies 
could be due to methodological variations. Given that our study used multiple 
sources including ECG, patient registers, and clinical examinations to identify 
AF cases from a general older population, it is likely that our study has captured 
more community-dwelling older adults with AF that had never come to medical 
attention than registry-based studies using only medical records to detect AF, thus 
reporting slightly higher estimates of AF prevalence. 
Our findings that no AF patient with low risk of stroke (i.e., CHADS2=0) at the 
time of baseline examination (2001-2004) was taking anticoagulant drugs were 
consistent with recommendations from consensus guidelines.[56] Women who 
have a CHA2DS2-VASc score of 1 (because of the sex) do not need anticoagu-
lant treatment, since they are at true low risk of incident stroke.[57] Yet, whether 
anticoagulant therapy is needed among men with a CHA2DS2-VASc score of 1 
is still a matter of debate;[164] this is possibly due to wide variabilities in the 
estimated risk of ischemic stroke among untreated men with a CHA2DS2-VASc 
score of 1.[54,165] 
Our study also showed that less than one-third of AF patients with a high risk of stroke 
(i.e., CHADS2 score ≥2 or CHA2DS2-VASc score ≥2) at baseline examination were 
using anticoagulant agents, which is considered low. On the other hand, compared 
to people using anticoagulant drugs, more than twice the participants with AF at 
baseline were using antiplatelets, which are not recommended to prevent ischemic 
stroke among older people with AF. As summarized in Figure 1, suboptimal anti-
coagulant treatment among older AF patients has been reported in many countries 
among previous register-based studies. Since our study included clinically undiag-
nosed (silent), thus untreated, older AF patients, the use of anticoagulant drugs in 
our study is even lower than register-based figures. Physicians are often reluctant to 
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prescribe anticoagulant drugs to very old people with AF due to concerns of major 
bleeding.[166] Indeed, our study showed that a high bleeding risk score is associ-
ated with not using anticoagulant agents among patients with a high risk of stroke. 
However, according to the ESC Clinical Practice Guidelines for AF, a high bleeding 
risk score shall warrant more frequent review of the patients rather than withdraw of 
anticoagulant treatment or inappropriate substitution with antiplatelets.[57]
Despite the suboptimal anticoagulant treatment among older people with AF at 
study baseline, the use of anticoagulant drugs among AF patients was substan-
tially higher at the 6-year follow-up examination (2007-2010). This increase was 
particularly evident among people with high risk of stroke or low risk of bleeding. 
However, by the end of study follow-up, still around 70% of those at high risk of 
stroke were not on anticoagulant treatment. Secular trends in the use of anticoagu-
lant agents among AF patients has been investigated by only a few register-based 
studies; most of these studies reported a suboptimal use of anticoagulant drugs 
by the end of study period despite a substantial increase during the follow-up 
period,[64,75,84,85] similar to our findings. While the observed improvement 
in the use of anticoagulant agents among AF patients may reflect dissemination 
of guideline recommendations into day-to-day clinical practice, more efforts are 
needed to further improve anticoagulant treatment among older people with AF. 
5.4 Atrial fibrillation, cognitive decline, and dementia
In Study III, among a general older population aged 60 years and over, people 
with AF demonstrated a faster decline in global cognitive function and a greater 
risk of incident dementia compared to those without AF over a 9-year follow-up 
period. As shown in the literature (Table 3), the association of AF with cognitive 
outcomes appears to be more evident among middle-aged or younger-old adults; 
among very old people, findings are rather mixed. Inconsistencies in previous find-
ings could be partially due to heterogeneous methodologies across studies, such 
as differences in sociodemographic characteristics of study populations, sample 
size, length of follow-up period, and proportions of dropouts. Importantly, given 
that the diagnosis of AF among older adults was often delayed,[49] our study 
accounted for incident AF in all the analyses in order to minimize the potential 
underestimation of the association between AF and cognitive outcomes. In our 
sub-analysis, the association between AF and a higher dementia risk remained 
even in the absence of clinical stroke/TIA, which is consistent with findings from 
several recent studies.[93,94,97]
Two main pathways have been proposed to underlie the link between AF and 
cognitive disorders, including cerebral hypoperfusion and vascular mechanisms 
such as cerebrovascular lesions.[121,167–169] Indeed, AF was associated with 
an increased risk of combined vascular and mixed dementia in our study, while 
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the association with the risk of AD was minimal. Several population-based stud-
ies have examined the link between AF and different dementia subtypes; some 
supported a higher risk of vascular dementia associated with AF,[103,170] while 
others suggested a higher risk for AD.[107,171] Yet most of these studies did 
not consider mixed dementia caused by both vascular and AD pathologies in the 
brain, which are of great clinical relevance given that most dementia cases are 
a mixture of cerebrovascular and neurodegenerative features that are difficult to 
disentangle, especially among very old people.[109] It has been suggested that in 
older people with insufficient load of AD pathologies to show clinical symptoms 
of dementia, additional vascular brain damage could hasten the development and 
progression of dementia syndromes.[109,142,172] In accordance with this view, 
our results showed an almost six-fold higher risk of combined vascular and mixed 
dementia associated with AF among APOE ε4 carriers, while no association was 
found among non-carriers of the ε4 allele. This indicates that the coexistence of 
AD pathologies related to APOE ε4 allele and cerebrovascular injuries associated 
with AF could result in a higher risk of dementia than either process alone.   
Our results of an association of AF with accelerated cognitive decline and an 
increased risk of dementia have potential therapeutic implications. Few studies 
have examined cognitive outcomes associated with the use of anticoagulant drugs 
among older AF patients. A recent retrospective study covering all hospitalized 
patients with a diagnosis of AF in Sweden between 2006 and 2014 reported a 
29% lower risk of dementia among patients with anticoagulant treatment than 
those without such treatment.[113] Similarly, a US study using healthcare data 
from Mayo Clinic reported a 20% lower risk of incident dementia over 10 years 
among AF patients using warfarin compared to those not on warfarin therapy.
[173] A meta-analysis in 2019 pooling data from five longitudinal studies reported 
a 20% lower risk of incident dementia among AF patients using warfarin com-
pared to those without anticoagulant treatment.[174] Our population-based study 
showed that the use of anticoagulant drugs (i.e., warfarin), but not antiplatelets, 
is associated with a 60%  reduced risk of incident dementia among older patients 
with AF, indicating an additional cognitive benefit of anticoagulant treatment 
apart from stroke prevention. Our results are also in line with the current consen-
sus guidelines that recommend anticoagulant drugs as the first-line treatment for 
stroke prevention, while the use of antiplatelets should be limited.[57] In the era 
of novel oral anticoagulant drugs (e.g., dabigatran, rivaroxaban, and apixaban), 
which offer comparable degrees of protection against ischemic stroke with a lower 
risk of intracranial hemorrhage than warfarin,[89,175] it is reasonable to hypoth-
esize that novel anticoagulant drugs may have advantages over warfarin in terms 
of protection against accelerated cognitive decline and dementia in people with 
AF. Future studies are warranted to confirm this hypothesis. 
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5.5 Potential mechanisms underlying the association 
between atrial fibrillation and cognitive dysfunction 
Several potential mechanisms have been proposed to explain the association 
between AF and cognitive dysfunction in old age, including pathophysiological 
cardiovascular changes associated with AF, pathways involved in the brain and 
heart connection, and structural brain abnormalities manifested as cerebral SVD, 
as summarized in Figure 10.  
5.5.1 Cerebral small vessel disease
Structural brain abnormalities in old age manifested as cerebral SVD are usually of 
vascular origin or resulted from mixed pathologies,[176] which put older adults at 
an increased risk of cognitive decline and dementia.[119,177] Therefore, cerebral 
SVD may be an important neuropathological mechanism underlying the observed 
association of AF with cognitive decline and dementia. Yet current evidence has 
been so far limited regarding the longitudinal association of AF with various cer-
ebral SVD neuroimaging makers. In Study IV, we investigated the associations of 
AF with a number of cerebral SVD markers including lacunes, PVS, WMH, and 
regional and global brain atrophy. We found that, in the absence of MRI-detected 
cerebral infarcts, AF is associated with an accelerated increase in WMH and 
lateral ventricular volume over the follow-up period. These results indicate that 
AF contributes to structural brain changes beyond brain infarction and that both 
cerebral microvascular and neurodegenerative pathways are possibly involved in 
this process, which mirrors the findings from Study III.
WMH reflect a process of axonal loss and demyelination as a consequence of 
chronic cerebral ischemia.[128,129] According to population-based studies, the 
presence and progression of WMH has been associated with several vascular risk 
factors including smoking, hypertension, and a history of cardiovascular diseases.
[178–180] Current evidence from population-based studies that links AF to WMH 
is still scarce. In contrast to our results, longitudinal data from the Framingham 
Offspring Study and the ARIC study did not show a significant association between 
AF and changes in WMH volume.[131,133] It is worth noting that the age-specific 
prevalence of AF in both studies are low, which might have led to an underesti-
mation of the association. With regard to brain atrophy, although the association 
between AF and total brain tissue loss was not statistically evident in our study, we 
did find an association of AF with increased lateral ventricular volume, which is 
consistent with previous findings from the ARIC study.[131] Enlargement of the 
lateral ventricle has been regarded as a surrogate marker of global brain atrophy due 
to the adaptive ability of the fluid-filled ventricular system.[181,182] Importantly, 
lateral ventricular enlargement not only reflects neurodegenerative neuron loss but 
also has been highly correlated with white matter lesions.[183–185] 
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5.5.2 Cerebral thromboembolism and hypoperfusion
Cerebral thromboembolism and hypoperfusion have been proposed as the main 
heart-brain pathways underlying the association of AF with structural brain abnor-
malities.[115,117] It has been well described that the abnormal hemostasis and 
hypercoagulable state in AF put patients at high risk of cerebral thromboembolisms 
and subsequent ischemic stroke.[186] However, clinically diagnosed strokes are 
only the tip of the iceberg of AF-related cerebral ischemia. Moreover, even in the 
absence of MRI-detected cerebral infarcts, AF can lead to substantial brain struc-
tural changes, as shown in Study IV. In addition to macroscopic brain infarction, 
cardiac and cerebral thromboembolic phenomenon may result in the accumulation 
of cerebral microinfarcts, which are beyond the resolution of conventional MRI, 
leading to subsequent WMH and brain atrophy.[187,188]
AF could also lead to cerebral hypoperfusion by virtue of beat-to-beat variations 
and reductions in cardiac output and blood pressure.[167] Evidence supporting a 
direct association between AF and cerebral hypoperfusion has recently emerged, 
as the Icelandic AGES-Reykjavik Study showed that people with persistent AF 
had lower cerebral blood flow and brain blood perfusion compared to the parox-
ysmal AF group and control group.[189] A meta-analysis of 24 cross-sectional 
studies reported that a high WMH load was strongly associated with lower cer-
ebral blood flow, however, whether cerebral hypoperfusion precludes WMH or 
vice versa remains unclear.[190] Furthermore, it has been proposed that cerebral 
hypoperfusion induces brain capillary degeneration and suboptimal energy delivery 
to neurons, which could further result in a progressive loss of brain tissue.[191]
Overall, it is likely that AF contributes to brain lesions through various mechanisms 
affecting both the macro- and micro-environment in the brain. Larger longitudinal 
population-based neuroimaging studies are needed to assess the relationship of AF 
with different pathophysiological and neuropathological pathways.
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Figure 10. A schematic overview of potential mechanisms linking atrial fibrillation to 
cognitive decline and dementia. LV =left ventricle.
5.6 Methodological considerations
In this doctoral thesis, two population-base studies, the KP (only in Study I) and 
the SNAC-K study, with similar study designs and protocols were used. Both stud-
ies have a generous sample size and comprehensive data were collected by almost 
the same data collection group of trained health-care professionals as objectively 
as possible following standard procedures. However, methodological issues may 
arise in all epidemiological studies, among which systematic error and random 
error are of most consideration.
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5.6.1 Systematic error (biases)
Systematic errors in epidemiological studies are broadly divided into three 
 categories: selection bias, information bias, and confounding. 
Selection bias
Selection bias comes about when the relationship between the exposure and the 
outcome differs for the participants and the non-participants in the study, result-
ing in either underestimation or overestimation of the association. Selection bias 
can occur both during the sampling and recruitment processes at study baseline 
and during the study follow-up where attrition might happen. In both KP and 
SNAC-K, the participation rates at baseline are considered high for older popula-
tions (76.4%  vs. 73.3%). People who declined to participate at baseline could be 
older, less educated, had more chronic diseases, and thus more likely to experi-
ence the study outcomes (e.g., dementia in Study III) than those who participated. 
On the other hand, those who declined could also be younger, still working (e.g., 
<65 years), and thus less likely to experience dementia. Due to the fact that peo-
ple who declined to attend the baseline examination had shorter survival time 
than those who participated, it is likely that the first scenario has occurred in this 
project, leading to an underestimation of the associations. During the follow-up 
examinations, given that the data collection group spent great efforts to keep the 
participants in the study, the dropout rates was low in both KP and SNAC-K cohorts 
and most of the non-participation occurred because of death (refers to Figures 2 
and 3 in the introduction section). In Study I and Study III, no participant was 
lost to follow-up due to death because we were able to include in the analytical 
samples people who died during the study period by using information from death 
certificates. However, we could still have underestimated the association between 
AF and dementia if participants died before developing dementia. Taken together, 
considering the non-participation at baseline and during the follow-up, it is likely 
that an underestimation of the observed associations might have occurred in this 
project. 
Information bias
Information bias can occur when the information collected from the participants 
is erroneous. Such information is regarded as misclassified, either differential or 
nondifferential, if the variable is categorical and the error leads to a person being 
classified into a wrong category. Nondifferential misclassification occurs when 
the exposure or disease (or both) is misclassified but the misclassification is not 
dependent on the person’s other status. This type of misclassification often leads 
to a dilution of the true association. In contrast, differential misclassification 
happens when the exposure is misclassified differently according to the person’s 
47
disease status, which often results in under- or overestimation of the associations. 
In general, to avoid misclassification, the trained heath care professions in both 
KP and SNAC-K assessed the participants as objectively as possible following 
standard procedures at both baseline and follow-up examinations. 
The potential misclassification of AF and cognitive outcomes (i.e., global cogni-
tion and dementia) in this doctoral project is more likely to be nondifferential, 
given that the identification of AF is unlikely to be dependent on the person’s 
cognitive status and vice versa. Although multiple sources are used in Studies 
II-IV to detect AF cases among the participants, we might still have missed some 
asymptomatic cases (silent AF). In addition, MMSE as a measure of global cog-
nitive function may not be sensitive enough to detect subtle changes in certain 
cognitive domains, especially among highly educated people such as the SNAC-K 
participants. Therefore, the association of AF with cognitive decline, dementia, 
and cerebral SVD markers in this thesis might have been underestimated. With 
regards to use of medications, because the collection of medication information of 
each participant partially relied on the medication containers participants brought 
to the interview, differential misclassification of use of medications might arise if 
cognitively impaired persons forgot to bring certain drugs. However, since prox-
ies of cognitively impaired participants were always consulted and the examining 
physician carefully reviewed the medical charts of each participant, the misclas-
sification of use of medications is minimized. The lack of data on the duration 
of antithrombotic treatment and the quality of anticoagulant control represents 
another limitation. However, this might have limited influence on results in Study 
III because the anticoagulant control is generally good in Sweden.[192]
Confounding
A confounder is a factor that is associated with both the exposure and the out-
come, but not in the causal pathway. In all the four individual studies in this thesis, 
we dealt with the issue of confounding bias by either stratifying or adjusting the 
analyses for potential confounders. However, unmeasured or unknown confound-
ers could still be present, and thus we cannot completely rule out the possibility 
of residual confounding. 
In pharmacoepidemiological studies, confounding by indication of drug use 
often occurs. This type of confounding arises when people who take a drug dif-
fer from those who do not based on the medical indication for which the drug is 
prescribed. In Study III, physicians might be reluctant to prescribe anticoagulant 
drugs to AF patients who had cognitive impairment, therefore, the protective effect 
of anticoagulant drugs against dementia could be overestimated. We dealt with 
this confounding by indication by using the propensity score to balance as many 
characteristics as possible that could differ between drug users and non-users, 
however, residual confounding might still exist. 
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5.6.2 Random error 
Random error includes sampling error and measurement error. In epidemiologi-
cal studies, sampling error is incurred when the characteristics of a population 
are estimated from a subsample of this population. Since not everyone from the 
population is included in the sample, statistics of the sample generally differ from 
the entire population. Sampling error can be reduced by increasing the sample 
size. Measurement error can occur due to limited precision in the tools, devices, 
or methods when measuring study variables. Measurement error can be reduced 
by repeating the measurements on the same individual and average them. 
5.6.3 Generalizability 
The ultimate goal of epidemiological studies is to generalize study findings to 
other populations or countries. However, the above-mentioned sampling errors 
and systematic biases might limit the generalizability of study results, which could 
be particularly relevant for prevalence or incidence studies. Given that the KP and 
SNAC-K cohorts included a sample of healthier Caucasians with higher socioeco-
nomic status from the Kungsholmen area of central Stockholm, the generalizability 
of Study I and Study II might be limited in less wealthy populations with different 
demographic and disease characteristics. For instance, the decreasing incidence of 
dementia in Study I might not be generalizable to Asian populations in which the 
cardiovascular profile might be different from the European populations. Indeed, 
an increasing trend in dementia incidence has been reported from China and Japan. 
On the other hand, investigations on the association between an exposure and a 
disease which has solid biological plausibility are less dependent on the statistical 
representativeness of the sample. It is believed that it is the biological knowledge, 
insight, and conjecture, instead of representativeness of the study subjects, that 
makes for a proper generalization.[193,194] Therefore, generalizability is made 
possible through not only a representative sample but also a good understanding 
of the biological principles and skillfully controlling for potential confounders. 
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6 CONCLUSION
1. From the late 1980s to the early 2010s, the incidence of dementia had 
declined among older adults in central Stockholm, Sweden; this decline 
is particularly evident among women and in people with low education. 
Improvements in lifestyle, cardiovascular health, and cognitive reserve over the 
study period could explain only a small part of the decline.
2. AF is more common than previously reported among people aged 60 years 
and over. The use of anticoagulant drugs among older people with AF increased 
from 2001-2004 to 2007-2010, especially among those at high risk of stroke 
or low risk of bleeding. However, still two-thirds of older people with AF who 
were at high stroke risk remained untreated with anticoagulant drugs.
3. AF is associated with an accelerated global cognitive decline and an 
increased risk of all-cause dementia, and vascular and mixed dementia in 
particular, among older people. Use of anticoagulant drugs, but not antiplatelet 
drugs, may prevent older adults with AF from developing dementia. 
4. AF is associated with an accelerated increase in white matter lesions and 
faster brain atrophy in the absence of cerebral infarcts. 
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7 RELEVANCE AND IMPLICATIONS
Global population aging has led to a dramatic increase in the proportion of older 
adults who are susceptible to age-related diseases such as dementia. Dementia has 
been recognized as a global public health priority, and the vast burden this devas-
tating disorder imposes on both individuals and the society has led to continued 
global efforts to tackle the dementia epidemic. Therefore, studying the temporal 
trends in the incidence of dementia in the general older population, identifying 
modifiable risk factors for dementia such as AF, and exploring the potential neu-
ropathological mechanisms linking AF to cognitive aging are critical for future 
planning and allocation of society’s resources as well as for preventive interven-
tions. For instance, while the absolute number of people with dementia will con-
tinue to increase alongside population aging, the finding of a declining incidence 
of dementia since the 1980s indicates that the future burden of dementia might be 
milder than previously anticipated. 
Findings from this doctoral thesis also have several clinical implications. First, 
our study revealed that AF is more common among older adults from the general 
population than previously reported, which calls for the initiation of screening 
program to improve the detection of asymptomatic AF both in the clinic settings 
and in the general population. Second, the underuse of anticoagulant drugs in AF 
patients at both baseline and six years later indicates that the dissemination of 
evidence-based medicine (guidelines) into the clinical settings still needs to be 
improved. Third, the independent association of AF with cognitive decline and 
dementia may help to identify AF patients at risk of dementia and allow for timely 
initiation of appropriate medical and preventive strategies (e.g., patient-centered 
intervention) to reduce dementia risk. These findings may also support the inclu-
sion of cognitive assessments in AF patients in the clinical diagnostic work-up 
as well as in future clinical trials involving AF patients. Fourth, our findings on 
the cognitive benefit of warfarin among older patients with AF underlines the 
importance of proper treatment of AF to not only prevent ischemic stroke but also 
delay cognitive decline and dementia onset. Future randomized controlled clinical 
trials on novel anticoagulant drugs among AF patients shall consider cognitive 
outcomes as a primary endpoint. Finally, our MRI findings that AF contributes to 
both cerebrovascular lesions and neurodegenerative features in the brain may aid 
in future research examining the specific neuropathological mechanisms behind 
the AF-dementia association. Furthermore, these findings may help to develop 
optimal anticoagulant regime and improve the risk estimation of ischemic stroke 
and dementia among older people with AF.
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8 FUTURE DIRECTIONS
This doctoral thesis contributes new knowledge to the existing literature regarding 
the occurrence of dementia and AF, the association of AF with cognitive and brain 
aging, and the cognitive benefits of anticoagulant treatment among older adults. 
Yet future research is needed to verify our main findings and to address the new 
research questions this thesis brings forward. 
First, future investigations are warranted to further examine factors other than 
those included in our study in explaining the decline in dementia incidence, in 
order to facilitate the development of intervention strategies and inform better 
policy decisions. Although we took into account the most relevant protective and 
risk factors of dementia, the role of other factors, such as early childhood condi-
tions,[195] reproductive spans and number of pregnancies among women,[196] 
leisure time physical activities in midlife,[197] cancer,[198] and toxic exposures 
(e.g., air pollution),[199,200] remains to be investigated.
Second, given that novel oral anticoagulant drugs are readily available in the market, 
it remains to be seen whether anticoagulant treatment has improved among older 
AF patients since the launch of such drugs. In addition, since novel anticoagulant 
drugs have several advantages over warfarin, whether they have stronger long-term 
protective effect than warfarin against dementia remains unclear, although initial 
data on this regard have provided some favorable evidence.[201] Moreover, given 
the plausibility of hypoperfusion hypothesis behind the AF-dementia association, 
whether rhythm control drugs or AF catheter ablation can also benefit cognitive 
function needs to be investigated. 
Finally, the exact biological and neuropathological mechanisms underlying the 
association between AF and cognitive dysfunction need to be better understood, 
in order to inform optimal therapeutic and preventive interventions of cognitive 
disorders in older AF patients. In particular, larger population-based neuroimaging 
studies with better scanning resolutions are needed to elucidate the association of 
AF with cerebral microinfarcts, microbleeds, and hypoperfusion. Additionally, 
whether and to what extent markers of cerebral SVD mediate the association of 
AF with cognitive decline and dementia is to be investigated in larger imaging 
studies with a longer follow-up period. 
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